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ABSTRACT
Background: Chronic pain is a common condition that has significant impact on
patients’ physical and psychological well-being. Pharmacotherapeutic management of
chronic pain differs on the basis of the cause pain. Pharmacists’ expertise of
pharmacological knowledge and patient care make them key players in managing chronic
pain.
Methods: A three-month prospective pilot study was carried out at primary care settings
including community pharmacies and family health teams. Patients were seen by
pharmacists at the initial visit, 2-week follow-up, and 3-month follow-up visit.
Pharmacists’ interventions consisted of patient assessments, medication reviews, care
plan recommendations, and patient education. Pain, quality of life, and medication
adherence were measured with Brief Pain Inventory (BPI), Short Form-36, and Morisky
Medication Adherence Scales-8, respectively.
Results: Thirteen patients were enrolled, one withdrew. There was no significant
improvement in pain or quality of life at 3-month follow-up. However, trends toward
improvement were found.
Conclusions: This study showed that interventions of primary care pharmacists had no
significant effect on pain or quality of life of patients with chronic pain. However,
positive trends towards reducing pain intensity and pain interference with patients’
general activity, mood, normal work, and sleep were found. The reason for this could be
due to small sample size, low implementation rate of pharmacist recommendations by
physicians, low patient adherence, or extended study period.
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1CHAPTER 1: INTRODUCTION
1.1 The nature of pain
1.1.1 Definition and classification
Pain is defined by the International Association for the Study of Pain (IASP) as “an
unpleasant sensory and emotional experience associated with actual or potential tissue
damage”.1 It is a natural feeling that every individual experiences at some point in their
lifetime,2 and is an important component of the body’s natural protection mechanism that
alerts people to avoid or escape from potential danger or damage.3 However, when pain
persists, it can be harmful. IASP defines chronic pain as "pain that persists beyond
normal tissue healing time, which is assumed to be three months".1 Unlike acute pain,
which is caused by identifiable trauma or injury, the causes of chronic pain are often
unclear.3 It “can be nociceptive, neuropathic, or both and may be caused by injury,
malignant conditions, or a variety of non–life-threatening conditions such as arthritis,
fibromyalgia, and neuropathy”.3 Since the etiology of chronic pain is varied and not
clearly known, the management of chronic pain is more challenging than acute pain.
1.1.2 Subjectivity of pain
The reality that pain is not only an indicator of body dysfunction but also an
individualized emotional experience forms the subjectivity of pain. A noxious stimulus
activates the nociceptors which as a result to this stimulus react by sending messages to
neurons in the brain through nervous system; the brain then translates these messages into
pain.3 The nociceptive system is plastic and it enables the neurons in the brain to modify
2their response to a stimulus in a specific environment so that different persons respond to
a same level of stimulus differently.3 In other words, stimulus alone cannot determine the
pain level. Age, gender, cognitive level, previous pain experience, and relevant
contextual and psychological factors also have significant impact.4
1.1.3 Psychological factors that influence the feeling of pain
As pain is a personal emotional experience, understanding psychological factors that
are associated with pain is essential. Negative emotions including anger, depression, and
anxiety have been proven to be associated with pain.5 Negative thoughts predispose
people to experience pain and in return, pain aggravates anger, depression, or anxiety. It
is difficult to say which one comes first. In most cases, they are concomitant. When anger,
anxiety, or depression is triggered by life events, the effect of medications becomes
limited. In these scenarios, optimism and self-management have been shown to have
beneficial effects.6
1.2 The prevalence of chronic pain
Chronic pain has become one of the most underestimated diseases affecting a large
population all over the world. An estimated 17% of the Canadian population aged 15
years or older experienced chronic pain.7 The estimates of the prevalence of chronic pain
among Canadians are reported to range from 15.3% to 55% with a higher prevalence in
females and the elderly.7-11 The National Population Health Survey revealed that the
prevalence of chronic pain among Canadians increased from 15.3% in 1996/1997 to
19.5% in 2004/2005.8 These studies defined chronic pain either as pain that lasts longer
than 3 months11or longer than 6 months,9,10 or as usual pain.7,8 In addition to the time
3frame, age, and gender, other factors that contribute to the variation are socioeconomic
status, educational level, employment status, and methodological differences. Such high
prevalence causes detrimental consequences at both individual and societal levels.
1.3 Burden of chronic pain
There is evidence that patients who suffer from chronic pain experience limitations
in social activities, an inability to work, and a poor quality of life.12,13 According to a
European survey, 79% of the respondents reported that pain had impacted their normal
activities. Approximately 26% said that their employment status was impacted by chronic
pain, and 21% had been diagnosed with depression.14 Patients’ inability to maintain an
independent lifestyle also impacted family members of sufferers.14,15 Since the duration
of chronic pain is always protracted, usually more than two years, all these consequences
place a heavy burden on patients and their families.14
Chronic pain also places a tremendous burden on the health system. The cost of
chronic pain in Canada was reported to be $47 to 60 billion per year.16 It was estimated
that the total cost of pain in the United States ranged from US$560 to US$635 billion a
year.17 Moreover, evidence indicated that compared to patients without chronic pain,
patients with chronic pain require health care resources more frequently.14 The cost will
likely continue to increase with the elevated prevalence rate.
1.4 Management of chronic pain in primary care
Managing chronic pain is challenging for healthcare providers. To determine the
best treatment options, clinicians should consider pain intensity, type of pain, and pain
quality.18 Before implementing any care plans, a comprehensive pain assessment is
4crucial. Although medications are considered as the core component in treating pain,
patients will benefit from a more multidimensional management plan.
1.4.1 Assessing pain
Ideally, a comprehensive assessment of a new patient consists of pain history review,
psychiatric comorbidity, psychosocial factors, risk of addiction, assessment of function,
treatment goals, and physical examination.6 In primary care, pain history reviews
involving the evaluation of the onset of pain, palliative care, quality of pain, pain sites,
pain intensity, duration, treatment history, and current treatments, plays a major role.
1.4.2 Pharmacological interventions
Chronic pain treatment mainly consists of pharmacological interventions and non-
pharmacological interventions. The focus on one aspect is not sufficient to achieve
appropriate pain relief.
Medications for chronic pain mainly consist of non-opioid analgesics and opioids.
Non-opioid analgesics include topical agents, NSAIDS/acetaminophen, antidepressants,
anticonvulsants, cannabinoids, NMDA inhibitors, and skeletal muscle relaxants.18
Opioids that are recommended in the Canadian guideline for chronic non-cancer pain
include codeine, tramadol, morphine, oxycodone/hydromorphone, fentanyl, and
methadone, among others.19
There is variability across different medications in terms of targeting pain types and
efficacy. For instance, tricyclic antidepressants (TCAs), serotonin and noradrenaline
reuptake inhibitor (SNRI) antidepressants, and anticonvulsants (gabapentin or pregabalin)
are the first line medications for neuropathic pain;20 non-steroidal anti-inflammatory
5drugs (NSAIDs), selective cyclooxygenase-2 (COX2) inhibitors, muscle relaxants, and
tramadol are top options for non-specific lower back pain;21 weak opioids (such as
tramadol and codeine) are recommended for patients with neuropathic or somatic pain
who have little response to first line treatments; stronger opioids (oxycodone,
hydromorphone, and morphine) can be considered when patients have no response to
weak opioids.19
A Cochrane systematic review of antidepressants for neuropathic pain which
included 61 randomized controlled trials (RCT), revealed that TCAs were effective in
treating neuropathic pain, with a numbers needed to treat of 3.6 (95% CI 3 to 4.5), and
relative risk 2.1 (95% CI 1.8 to 2.5) to achieve at least moderate pain control. TCAs were
proven to be effective in treating diabetic neuropathy and post herpetic neuralgia, while
evidence of the effectiveness of the selective serotonin and norepinephrine reuptake
inhibitors (SSRIs) was quite limited.22 A systematic review which covered 6 RCTs and
2220 patients investigated the efficacy of duloxetine in treating painful neuropathy or
chronic pain and found moderately strong evidence that duloxetine 60 mg and 120 mg
daily were efficacious compared to placebo in treating painful diabetic peripheral
neuropathy and fibromyalgia.23
There was moderate evidence that gabapentin at doses of 1200 mg or more daily
was more effective than a placebo for people with painful diabetic neuropathy (38%
versus 21%) and post-herpetic neuralgia (34% versus 21%). However, there were
significantly more adverse effects with gabapentin than with placebo and caused side
effects including, somnolence, peripheral oedema, dizziness, and gait disturbance.24
6NSAIDs, as the most frequently used drugs on pain management, were slightly more
effective in treating low back pain compared to a placebo but had significantly greater
side effects such as gastrointestinal (GI) bleeding, hypertension, peptic ulcer disease,
renal disease, and edema.25,26
Opioids showed no significant advantages over non-opioids for pain intensity, but
were slightly worse than non-opioids for functional outcomes. In addition, compared to a
placebo, opioids resulted in significantly higher reporting of constipation, nausea,
dizziness or vertigo, somnolence or drowsiness, vomiting, and dry skin, itching or
pruritus.27
1.4.3 Non-pharmacological interventions
Physical interventions and psychological interventions form the basis of non-
pharmacological interventions. Physical interventions include massages, the avoidance of
bed rest/staying active, physical exercise, therapeutic exercise/physiotherapy,
acupuncture, ultrasound, electrical stimulation, traction, exercise, cryotherapy, and heat
therapy.28 Psychological interventions consist of biofeedback, relaxation training,
hypnosis, and cognitive-behavioral therapy.29 The effectiveness of the non-
pharmacological interventions is unclear and varies from one individual to another.29-33
1.5 Problems in chronic pain management
The management of chronic pain remains suboptimal. It was reported by primary
care providers from Canada that 60% of chronic non-cancer pain patients experienced
improperly controlled pain,34 which is comparable to a European survey (more than
50%).14 According to this survey, 40% of Europeans who are suffering from chronic pain
7demonstrated that they would be willing to spend all of their money on pain management
if the treatments were effective, which indicated their despair in seeking good pain
management.14 In order to achieve pain relief, we ought to be clear of the obstacles in the
way.
1.5.1 Treatment-related problems
The most significant problem in chronic pain management is the lack of effective
medications. As mentioned above, despite certain types of drugs, the efficacy of pain
medications remains unsatisfactory. In contrast, analgesics can lead to considerable side
effects. This reality leaves a challenge to health professionals to carefully compare the
benefits over the risks. What makes the situation even worse is that chronic pain is often
accompanied with psychological disorders such as depression, anxiety, fatigue and sleep
disturbances.35 These multiple conditions always require poly-pharmacy, “the use of two
or more medications”,36 which eventually increases the risk of side effects and drug
interactions. As highlighted by physicians, side effects, low patient compliance, and
concerns about the efficacy of available therapeutic options are three major barriers that
prevent patients from obtaining optimal outcomes.37
1.5.2 Knowledge-related barriers
The importance of knowledge, attitudes and beliefs of patients and healthcare
providers towards pain management has been well-documented.37-43
In the European survey, in which in-depth interviewes were conducted among 4839
chronic pain patients from 15 European countries and Israel,14 when patients were asked
about attitudes and beliefs about pain treatments, 63% of respondents indicated their
8concerns with potential sides effects of pain, more than 50% commented that they would
rather take medication for their illness than their pain, and 48% were concerned about
addiction. This situation may reflect that patients failed to receive adequate education and
information regarding pain therapies. This is compounded by the fact that about 30%
patients are constantly receiving inaccurate information regarding their pain conditions
from their caregivers.14
Although physicians and pharmacists are accepted as well-educated and trustworthy
healthcare providers, they may be not knowledgeable enough or well prepared for pain
management as evidenced by the European survey mentioned above.14 When asked how
their doctors evaluated their pain, 71% of the interviewers responded that evaluation was
limited to verbal as self-reported, 52% were examined by their doctor, and less than 10%
were assessed with a pain scale which is considered as the most reliable pain measure;
furthermore, 43% of participants mentioned that they had a feeling of “my doctor would
rather treat my illness than my pain”, 40% indicated their pain was ignored by their
doctors, and 30% said their doctor did not know how to treat their pain. A Canadian
survey evaluating the knowledge, attitudes, and beliefs of pharmacists and physicians
about chronic pain confirmed the situation, in which both physician and pharmacists
received less than satisfactory performance in assessing pain, defining treatment goals
and expectations, and developing treatment plans.44 Additionally, more education on pain
management is beneficial from healthcare providers’ perspective.44,45
1.5.3 Satisfaction
In patient-focused care, patient satisfaction is considered an important indicator
when evaluating the quality and effectiveness of healthcare services. Although
9satisfaction may not solely reflect the effectiveness of treatments, dissatisfaction may
lead to the break of the trust between patients and healthcare providers, which in return
will worsen patients’ psychological conditions and hence impact their pain. In the
European survey,14 40% of respondents were dissatisfied with the treatment, 56% felt
their medication somewhat effective or not effective at all, and 38% felt dissatisfied or
only somewhat satisfied with their doctors.
1.6 Why and how can primary care pharmacists help in managing
chronic pain
1.6.1 Education
Pharmacists receive comprehensive education in terms of pharmaceutical sciences,
therapeutics, and communication skills at the undergraduate level. They are trained to
develop individualized drug therapy plans, identify complex drug interactions, monitor
side effects, and establish good relationships with patients and other health professionals.
Apart from common pharmaceutical knowledge, pharmacy schools in Canada also offer
mandatory pain-specific curricula. A survey investigating pain curricula in health science
faculties in Canadian universities highlighted that the average hours for designated
mandatory pain content in pharmacy were 13 hours with emphasis on pathophysiology of
pain, etiology/prevalence, misbeliefs/barriers and challenges, assessment,
pharmacological treatments (analgesics and adverse effects), non-pharmacological
treatments, multidimensional nature of pain and management implications, and
monitoring and policy/guidelines, while that in medicine and nursing school was 15
10
hours and 31 hours respectively.46 Evidence showed pain education programs can
significantly improve pain knowledge and beliefs of health professionals. 37,38,44
1.6.2 Services provided by pharmacists in community pharmacies
Community pharmacists are the most accessible and frequently visited health
professionals.47 This advantage enables pharmacists to develop a close relationship with
patients, which is fundamental to the achievement of pain relief. Pharmacists’ role used
to be restricted to dispensing medications and compounding. Following the trend of
patient-focused care, Canada has continually expanded the scope of pharmacy practice in
the last two decades.48 As demonstrated in “Model Standards of Practice for Canadian
Pharmacists”, pharmacists’ roles include patient care, drug information, drug distribution,
management, and education.49
1.6.3 Services provided by pharmacists in multi-disciplinary teams
A pharmacist in a multi-disciplinary team acts as an information provider, as well as
a bridge connecting doctors and patients. For instance, a pharmacist in a multi-
disciplinary pain management team provides services such as patient assessment,
consultation, care plan recommendations, and education. After these interactions with
patients, pharmacists relay this information to physicians and also discuss patients’
concerns regarding medications. This significantly improves the understanding between
doctors and patients. 50
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1.6.4 Evidence
Evidence of the effectiveness of pharmacists’ intervention is well-documented.51,52
A systematic review and meta-analysis of 400 patients illustrated that educational
interventions provided by pharmacists significantly decreased average pain intensity by
5%, reduced adverse effects by more than 50%, and improved patient satisfaction with
treatment by approximately 10%.52 Another systematic review/meta-analysis investigated
the effectiveness of medication review provided by pharmacists from primary care in
patients with chronic non-cancer pain. This review found an 8% and 5% pain intensity
reduction at 3 and 6 months post-intervention respectively, a significant improvement in
physical functioning at 3 months, and a significant improvement in patient satisfaction.51
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CHAPTER 2: A Systematic Review of Primary Care
Pharmacist Interventions in Chronic Pain
(This chapter will be submitted for publication at a future date)
2.1 Background
While acute pain is an important component of the body’s normal protection
mechanism by alerting it to danger or damage, chronic pain can be harmful or detrimental
to a patient’s health. 2,53 Between 15.3% to 55% of Canadians experience chronic pain,
with a higher prevalence in females and the elderly.7-10,54 Chronic pain limits social
activities, ability to work, and quality of life,13,55 and is associated with psychological
disorders such as depression, anxiety, fatigue, and sleep disturbances.35 Soaring
medication costs drain patient resources,8 and patients with chronic pain use clinic visits
and inpatient care more frequently than those without chronic pain.14 Thus, chronic pain
has a negative impact on income, and, together with the high cost of pain treatment,
places a significant economic burden on individuals and society.
The management of chronic pain remains suboptimal as demonstrated by the fact
that 66% of chronic pain patients report that they experienced pain for more than five
years.14 Issues around medication use include lack of effective medications, inappropriate
poly-pharmacy, numerous side-effects, and medications that decrease pain intensity but
do not result in pain relief. Furthermore, the effectiveness of non-pharmacological
interventions such as exercise and cognitive-behavioural programmes are inadequately
investigated or reported and may be underutilized.56,57
Pharmacists use their expertise in identifying drug therapy problems to become key
players in multi-disciplinary teams. Pharmacists can also monitor the efficacy and safety
13
of treatment and educate patients. Since appointments are generally not necessary, and
pharmacies often have longer hours of peration than medical clinics, they are the most
accessible health professionals. This provides numerous opportunities for patients to
consult with pharmacists about medications and conditions.14 The interactions between
patients and pharmacists enhances patents’ knowledge of pain and pain medications and
can contribute to their confidence in their ability to manage pain.
Two recent systematic reviews evaluated the effectiveness of pharmacist-provided
medication reviews and educational interventions, and supported the effectiveness of
pharmacist intervention in reducing pain intensity and improving patient satisfaction.52,58
As no systematic review has evaluated the effectiveness of various pharmacist
interventions on ambulatory patients with chronic pain, a comprehensive literature review
of all types of pharmacist interventions is necessary to determine a more fulsome
understanding of the impact of pharmacist intervention on chronic pain. The intent of this
systematic review is to investigate the process of delivering interventions by community-
based pharmacists and the outcomes of the intervention in ambulatory patients with
chronic pain.
2.2 Methods
We followed the 27-item PRISMA guidelines in conducting the present systematic
review.59
2.2.1 Selection of studies
With the assistance of a medical librarian, comprehensive electronic searches of the
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL),
14
COCHRANE, Psych Info, EMBASE, and International Pharmaceutical Abstract (IPA)
databases were conducted of English language publications up to July 2015 using the
search terms presented in Table 1. Manual searches of bibliographies were performed and
bibliographies of retrieved articles were examined for additional relevant articles, but
grey literature was not included.
Inclusion criteria: All RCTs and all non-randomized studies (N-RS) that involved a
pharmacist who directly dealt with managing chronic non-cancer pain were included.
Team-based approaches to chronic non-cancer pain management were considered only if
a pharmacist was included. Pharmacists working in primary care settings such as
community pharmacies, primary care teams, pain specialty clinics, or general practices
were included. Ambulatory patients with chronic non-cancer pain were included.
Exclusion criteria: Studies presented in abstract only, editorials, commentary, and
reviews were excluded. Patients residing in long-term care facilities, retirement homes,
and institutionalized settings, or with cancer pain were excluded. Studies that were not
published in English were excluded.
Two reviewers (Mo Chen (MC) and Trupti Kulkarni (TK)) performed searches and
screened the titles and abstracts independently. Full papers were retrieved if they
appeared to meet the inclusion criteria and were reviewed independently by reviewers for
inclusion. The corresponding authors of studies published as abstracts were contacted to
determine whether a full-length paper had been published. Disagreements about inclusion
between the any reviewers were resolved by a third reviewer (Feng Chang (FC) or Tejal
Patel (TP)).
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2.2.2 Data extraction and coding of outcome measures
The primary outcome measures were change in any measures of pain on scales for
pain intensity or pain relief; change in quality of life measures of patients; and the
pharmacist intervention processes. The secondary outcomes were changes in measures of
anxiety, depression, and disability; changes in health resource usage (including patient
referral to other healthcare professionals, cost, and number of clinic visits); changes in
dosing or consumption of pain medications; reduction in adverse events; measures of
patient satisfaction with interventions; and the acceptance of the interventions by the
physicians. For convenience, we coded these outcomes as patient-reported improvement
(Outcome 1), the acceptance of the intervention (Outcome 2), health resource usage
(Outcome 3), and change of medication use (Outcome 4).
Two reviewers (MC, TK) independently extracted data using a pre-designed data
extraction form. Disagreements were resolved by discussion with a third reviewer (FC or
TP).
2.2.3 Risk of bias in included studies
We used the risk of bias tool of The Cochrane Collaboration to assess risk of bias in
the RCT,60 and A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies
of Interventions (ACROBAT-N-RSI), recently developed by the Cochrane
Collaboration,61 to assess the risk of bias on outcomes of each N-RS. Descriptive studies
that only described how a health site worked but did not apply a study design were not
subject to risk of bias assessment. Potential confounders affecting each of the outcomes
of the N-RS were identified and are presented in Table 2.
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Each of the included studies was assessed for bias independently by two
investigators (MC, TK), then cross-checked and discussed by the two investigators.
Disagreements were resolved by a third reviewer (FC or TP) or through group (FC, TP,
MC, and TK) discussion.
2.3 Results
The initial search yielded 1077 records. After removing duplicates, 682 titles and
abstracts were screened, resulting in the exclusion of 646 records, and leaving 36 full-text
articles for full-text retrieval. After assessing the eligibility, seventeen articles met all of
inclusion criteria and none of the exclusion criteria, describing the results of fourteen
separate studies. Figure 1 illustrates the search and selection process.
2.3.1 Characteristics of the included studies
Of the 14 studies, seven were conducted in the United States,62-68 five in the United
Kingdom,69-73 one in Belgium,74 and one in Canada.75 Three studies were RCT,62,70,71 and
eleven were observational studies including cohort studies, descriptive studies, and
retrospective studies.63-69,72-75 Three studies defined chronic pain as pain persisting longer
than three months,63,70,72 1 defined it as longer than 6 months,76 while the remaining
studies did not provide a definition. The characteristics of each of the studies are
summarized in Table 3. The risk of bias is summarized in Tables 4 and 5 for RCT and N-
RS, respectively. The RCTs were judged to have lower risk of bias than the N-RS.
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2.3.2 The delivery of pharmacist intervention
Five of the studies applied a pharmacist-only approach,67,70-73 and nine involved
pharmacists and other health professionals such as physicians and nurses.62-66,74
2.3.2.1 Pharmacists only approach
In the study conducted by Kroner et al.,67 the pharmacist documented any
medication conversion that was performed and assessed for serious adverse effects
associated with medication conversion using the Naranjo Scale.77 Medication conversions
involved both inter-class and between-class ones, such as gabapentin converted to
amitriptyline.
Bruhn et al. assigned participants to one of three arms.70 Patients in the prescribing
arm were requested to complete a pain diary before an in-person consultation with a
pharmacist for pharmacist prescribing and medication review. Pharmacists then
developed a therapeutic plan agreeable to both patient and pharmacist and followed up
patients afterwards. On average, the paper-based medication review took thirty-five
minutes, the consultation took thirty minutes, the care plan took ten minutes to formulate
and the follow-up was ten minutes. The patients in the review arm received a paper-based
medication review and a pharmaceutical care plan. The controls received standard care as
usual.
The RCT conducted by Hay et al. also divided participants into three groups.71 The
intervention in the enhanced pharmacy review group involved three to six patient
consultations over a 10-week period. During the medication reviews, the pharmacist
made treatment recommendations based on a pre-defined algorithm in which proper
medications were added step-by-step based on patients’ pain control and provided
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education and advice on medicines and relevant lifestyle factors. Community
physiotherapy group received care from community physiotherapists. Participants in the
control group received the same advice and information leaflet as the other groups but no
interventions.
In the McDermott et al. study,72 pharmacists reviewed patient prescribing records
and identified 230 chronic pain patients who were sent a baseline questionnaire and a 6-
month follow-up questionnaire. In-person interviews were conducted with 25% of
randomly selected patients. During the interview, the pharmacist explored medication use,
side effects experienced, and satisfaction with the medications, making recommendations
if necessary. The results of the assessment and recommendations were sent to the
appropriate physician.
In their study, Read et al. involved pharmacist-conducted structured interviews with
rheumatoid arthritis patients to identify perceived side effects.73 This resulted in the
identification of twenty-eight patients with poor outcomes, leading to recommendations
for a change of therapy for twenty-four of these patients that were subsequently discussed
with the general practitioner. Advice from the pharmacist was given to improve efficacy,
compliance, knowledge of medicine, and to minimize adverse effects.
2.3.2.2 Multi-Disciplinary Approach
The Bauters et al. study analyzed outpatient’s medication data for nine months at
Belgian Ghent University Hospital.74 The clinical pharmacist performed 120
interventions for 93 patients that included clinical interventions (89.2%), providing
medication information (10%), and provision of a specific product (0.8%). Clinical
interventions were increasing therapeutic drug monitoring (35.5%), changing therapy
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(20.6%), stopping a medication (19.6%), starting a medication (19.6%), and clarifying a
prescription (4.7%). The majority of the stopped, started, or changed medications were
related to analgesics and anti-depressants.
In the Gammaitoni et al. study,62 the intervention contained two components;
specialized prescription services offered by a palliative care pharmaceutical company to
improve the delivery of medications, the other was a palliative-trained pharmacist’s effort
to monitor patients’ medication use and outcomes, by asking patients a series of pre-
defined questions during telephone or office visits. Pharmacists made forty-five calls
(56% of total) to patients, averaging twelve minutes per call.
In the Dole et al. study,63 an average of 18 patients per day were seen by a team of
pharmacists, clinicians, and nurse practitioners. A clinical pharmacist with prescribing
authority met with the patient for twenty minutes, with a ten-minute follow-up at an
unspecified interval. At each visit, the patient was asked to fill a Visual Analogue Scale
(VAS, a ten-point pain scale).78 VAS scores were measured up to the tenth visit. A
pharmacist-developed medication refill protocol to standardize the medication refill
process was assessed by measuring the number of near-miss medication errors. Finally, a
controlled substance monitoring program was initiated.
In the Chelminski et al. study,64 pharmacists performed structured clinical
assessments of the patients, followed by monthly follow-ups. During the assessment,
patients were asked to sign pain contracts. Pharmacists also adjusted medication doses,
recommended psychiatric consultation if deemed helpful, and monitored for substance
abuse.
20
In the Suzuki et al. study,65 the pharmacist, who had pain expertise, offered
interventions including initial evaluation, buprenorphine inductions, and follow-up visits.
Initially, patients were seen weekly, but after achieving clinical stability for at least four
weeks, the visits decreased to bi-weekly, and then monthly.
In the study reported by Cunningham et al.,66 the pharmacist was responsible for
reviewing medications of patients and calculating the costs of the necessary medications
at admission and again at discharge. Education was provided on medication use, efficacy,
side effects, and any withdrawal effects.
Wiedemer et al. assessed an Opioid Renewal Clinic (ORC) managed by a
pharmacist and a nurse practitioner to support primary care providers (PCPs) from a
university-affiliated tertiary care center.68 Initially, a pharmacist and a nurse practitioner
met with a multidisciplinary pain management team biweekly to receive advice on
treatment plans. Most cases were managed by PCPs and the pharmacist. Interventions
included individualized treatment plans, monitoring, prescribing, pill counts, counseling,
and education.
Briggs et al. evaluated a program run by a pharmacist and a nurse.69 In the study,
pharmacists conducted medication reviews and assessed pain scored on an eleven-point
scale. The nurses and pharmacists then worked together on treatment plans, which were
reviewed by physicians.
In the Turner et al. study,75 community pharmacists displayed posters in the
pharmacy requesting patients taking headache medications more than twice weekly to
speak with their pharmacist. Pharmacists then provided education pamphlets to patients
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who experienced medication induced headaches (MIH) and requested them to contact
study nurses to log potential MIH patients.
2.3.3 Pain scores
While pain measures were reported in 10 of the 14 studies,62-66,69-73 scales by which
pain was measured varied. Suzuki et al. measured both pain intensity and pain
interference using BPI.79 Chelminski et al. applied the BPI to measure pain intensity and
the Pain Disability Index (PDI) to measure pain disability.80 McDermott et al. and Bruhn
et al. reported pain intensity and pain disability using Chronic Pain Grades (CPG), which
classify patients into five categories: grades zero (no pain) to four (high disability-
severely limiting).81 Cunningham et al. measured pain intensity and psychosocial
functioning with the Multidimensional Pain Inventory (MPI).82 Dole et al. and Read et al.
reported pain intensity with a Visual Analogue Scale (VAS), which is a straight line
where the start represents no pain and the end represents the worst pain.78 Briggs et al.
measured pain intensity according to a zero to ten on the Numerical Rating Scale (NRS),
a scale where zero represents no pain and ten represents unimaginable pain.83
Gammaitoni et al. assessed pain with the Pharmacotherapeutic Pain Inventory (PhPI),
which was derived from the BPI and Health Background Questionnaire-Initial Patient
Visit.62 Hay et al. applied both NRS and the Pain and Physical Function subscale of the
Western Ontario and McMaster Universities osteoarthritis index (WOMAC) to measure
pain.84
2.3.3.1 Pain intensity
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Only 5 of the 10 studies reported significant reductions in pain intensity from
baseline to follow-up,63,64,66,69,70 2 studies found significant reduction in pain intensity
compared to controls at follow-ups.70,71 Results from Suzuki et al., McDermott et al., and
Read et al. studies also indicated improvement on pain intensity, but the significance of
the improvement was not reported.65,72,73 Hay et al. reported significant reduction of pain
intensity in the pharmacy review arm using both the WOMAC pain intensity subscale
and NRS compared with controls at three months, but not at six months or one year.71 In
the Bruhn et al. study, pain intensity reduced significantly within the prescribing arm at
the six-month follow-up, but not in the review arm or control arm; compared to baseline,
47.7% (p=0.003) patients in the prescribing arm achieved improvement and 38.6%
(p=0.001) in the review arm.70 No significant pain intensity reduction was found in the
Gammaitoni et al. study.62
2.3.3.2 Pain interference
Seven studies measured pain interference. Chelminski et al. reported significant
improvement in pain disability with PDI at 3 months.64 Bruhn et al. determined a
significant reduction in pain disability in the prescribing arm at 6 months follow-up, pain
disability was not reduced in the review or control arms,70 no significant between-arm
result was found. Suzuki et al. reported an improvement in pain disability without
evaluating the significance.65 Hay et al. did not find significant differences between the
pharmacy review arm and the control arm at all the three time intervals in physical
functioning.71 Perceived life control and general activity level which were measured by
MPI in Cunningham et al. study both showed significant improvement.66 At the three-
month follow-up of the Gammaitoni et al. study, the intervention group got significantly
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better treatment relief than did the control group, but no significant results were found in
pain interference with general activity, mood, walking, normal work, relationships, or
enjoyment of life, despite significant improvement in physical and emotional problems
interference with social life within the intervention group.62 No significant improvement
in pain interference was found in the intervention group when comparing baseline with
the three-month follow-up.62
2.3.4 Quality of life
Only three of the fourteen studies reported on the quality of life of patients.66,70,75
Turner et al. measured the quality of life of patients with The Henry Ford Hospital
Headache Disability Inventory (HDI), a headache-specific instrument with emotional and
functional domains,85 and The Medical Outcome Study (MOS) short-form general health
survey, a valid and reliable generic instrument.86 Bruhn et al. reported quality of life with
Short Form-12 and Health Utilities Index-3 (HUI-3), a generic preference-based health
state utilities measure.87,88 The Neilson et al. study, which was linked to the Bruhn et al.
study, used the Short Form-6-Dimension questionnaire (SF-6D), which is a generic
patient preference-scored instrument for measuring quality of life.89 Cunningham et al.
assessed quality of life using the Short Form-36, a generic instrument with 36 items.90
Turner et al. found a consistent, but not statistically significant trend toward
improvement.75 In the Bruhn et al. trial, only the control group showed statistically
significant improvement in the physical component score of the SF-12, but a significant
decrease in mental component score; no significant improvement was found in both
prescribing arm and review arm. Neilson et al. reported that the SF-6D health utility
scores were similar in all three arms at all three time points, and a slight improvement in
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follow-ups compared to baseline.91 The health perception and physical functioning
subscales of SF-36 improved significantly from admission to six-month follow-up in the
Cunningham et al. study.66
2.3.5. Other outcomes
2.3.5.1 Depression and anxiety
Depression was reported in three studies using either the Hospital Anxiety and
Depression Scale (HADS) or the Centre for Epidemiologic Studies Depression Scale
(CES-D).92,93 One study measured anxiety with HADS.93 CES-D is a self-reported
depression scale with scores ranging from 0 to 60 with higher score indicating increasing
severity in depression status.92 HADS is a 14-item screening tool with 7 items detecting
anxiety and 7 items detecting depression; each subscale scored from 0 (not present) to 21
(highly present).93
All of the three studies showed significant depression score reduction compared to
baseline in patients who received pharmacist intervention. In Bruhn et al. study, only
pharmacist prescribing arm reported significant improvement in depression and anxiety.70
2.3.5.2 Satisfaction and acceptance
Pharmacist interventions were highly accepted by physicians and patients. Bauters et
al. and McDermott et al. reported that 95.3% and 77% of the recommendations made
were accepted by physicians respectively.72,74 Of the primary care providers in the
Wiedemer et al. study, 84% were satisfied with the service.68 The recommended
treatment was accepted by 95.6% of patients in the Suzuki et al. study and 55% remained
enrolled at the six-month follow-up.65 In the Hay et al. study, 67%, 57%, and 52%
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patients were satisfied with the treatment at three months, six months, and one year post-
randomization, respectively.71 Briggs et al. reported that 92% of patients were satisfied,69
while in the Kroner et al. study, 24 of 47 patients persisted with the new medication after
a year.67
2.3.5.3 Cost
In addition, the twenty-four patients who remained in treatment in the Kroner et al.
study avoided $50,000 in medication costs.67 The pain clinic described by Dole et al.
generated $107,550 of actual revenues and saved health plans $450,000.63 Cunningham et
al. also achieved significant savings in medication costs admission to discharge.66
However, Neilson et al. concluded that pharmacist interventions were more costly, but
provided similar health benefits as controls.91
2.3.5.4 Medication usage
Both the Cunningham and Turner studies reported a decrease in medication use.66,75
Self-reported use of non-steroidal anti-inflammatory drugs in the pharmacy review group
was significantly lower than in control group, while the use of analgesics was higher in
the Hay et al. study.71 Contrarily, 48% of the patients in the Chelminski et al. study
increased their opioid dose over three months, and the mean opioid equivalent increased
from 53 mg to 105 mg per day.64
2.3.5.5 Health resource usage
Briggs et al. reported reduced need for secondary referral at 6-month follow-up,
while Wiedemer et al. found a decreased number of ER visits following pharmacist
intervention.68,69
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2.4 Discussion
In this systematic review, seventeen published reports were reviewed and appraised
to determine effects of pharmacist intervention on ambulatory patients with chronic pain.
In the majority of published reports, pharmacists worked in multi-disciplinary pain
management teams. The most frequently used pharmacist interventions was consultation
that involved medication reviews, recommendations, follow-ups, and patient education.
While there was variation in the scales used to measure pain and other outcomes, most
showed positive results.
Medication is an important component in managing chronic pain and pharmacists, as
trusted health professionals, contribute their pharmaceutical expertise in identifying drug
therapy problems to improve the management of pain. Consultations with patients enable
pharmacists to address patient concerns about their medications and pain problems, and
to educate patients about chronic pain. Since pharmacist interventions involved in
included studies were not single-itemed but a combination of different interventions, it is
not practical to determine which part of the intervention was most or more effective. For
example, Bruhn et al. found that 47.7% of patients in the prescribing arm and 38.6% of
those in the review arm reported significantly improved CPG scores, but those in the
control arm did not,70 suggesting that prescribing is more effective than medication
review, and that medication review is more effective than usual care. However, the SF-12
physical component score only showed a significant improvement in the control arm, but
not in the prescribing or review arms, making it difficult to draw a conclusion.
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We included studies from four different countries where the scope of pharmacist
practice varied. For instance, in UK pharmacists can prescribe independently within their
competence,94 certain areas of the USA permit protocol-based prescribing by pharmacists
while pharmacists in most parts of Canada cannot independently prescribe medications.
In addition, pharmacists practiced in different settings, some pharmacists worked in
multi-disciplinary teams, some saw patients independently. The variety of settings and
scope of pharmacist practice impacts pharmacists’ ability to independently make changes
to patients’ drug therapy.
The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) identified pain intensity and physical and emotional functioning as the
leading two core outcome measures for their chronic pain trial, 95 which is accordant with
the primary outcomes in this review. The reduction in pain intensity of patients who
received pharmacist intervention ranged from 1.5%-35%, of which some reductions were
significant, some were not, and three months post-intervention showed preferable
outcomes compared to six months post-intervention. Additionally, the clinical
significance of the improvement of pain interference needs to be investigated. A 30%
reduction on an eleven-point pain intensity rating scale is considered clinically
significant.96 The only study that achieved pain intensity reduction of 35% did not
generate statistical significance due to small sample size and high rate of patients lost to
follow-up.65 Bruhn et al. found significant improvement in pain scores in both pharmacist
intervention groups but no significant improvement in quality of life in either group, in
which the intervention consisted of prescribing and medication review.70 Only one study
from Cunningham et al. where pharmacist did a detailed interview with patient at
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admission and discharge demonstrated significant pain score reduction of 25% as well as
significantly improved health perception and physical functioning in SF-36 (p<0.001).
However, the variety of pain measures used in these studies, together with the
subjectiveness of rating pain, which is affected by baseline pain characteristics and
patient demographics, suggest that even a small reduction in pain may present a
significant improvement for some patients.
2.5 Limitations
There are several limitations in this review. Firstly, most of the included studies
were observational studies without control groups, making the data subjective. As the risk
of bias of assessment showed, the majority of the included studies had serious or critical
risk of bias. Secondly, most of the studies were conducted at a single site and had small
sample sizes, thus decreasing the generalizability of the findings and power of the results.
Furthermore, some of the outcomes being evaluated were patient-reported, which are
usually influenced by the baseline characteristics such as demographics. With the
exception of the Suzuki et al. study, the N-RS fails to adjust for these baseline
characteristics which might have confounded the results, so the precision of the results is
unclear. Aside from the limitations in study designs, the limitations of this review reside
in the inability to include potentially relevant articles due to availability of inadequate
data as they were published as abstracts only. Attempts to contact authors did not yield
additional information. Lastly, articles published in non-English languages that might
have been relevant to our review were excluded.
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2.6 Conclusions
This systematic review demonstrates that pharmacist-provided interventions were
effective in decreasing pain intensity, improving quality of life, and reducing cost and
side effects in patients with chronic pain. However, results are limited by the quality of
studies involved.
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Table 1: Key terms
Pain Location Personnel Intervention Efficacy
Chronic pain-MESH Community pharmacy Pharmacists Health services-MESH Effectiveness of intervention
Widespread pain- MESH Community-dwelling patients Outpatient pharmacist Effects of pharmacists Effectiveness of treatment
Recurrent pain Outpatient health Healthcare professional Treatment of chronic pain Evaluation of intervention
Lasting pain Clinic visit Health personnel Intervention Efficacy
Ambulatory care –MESH Management of chronic pain
Clinical pharmacy Patient care
Pharmacy Therapy
Educational intervention
Search terms within each column were combined using “OR” and “AND”.
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Table 2:Potential confounders of each outcome
Outcomes 1. Patient-reported improvement 2. Acceptance of intervention 3. Health resource usage 4. Change of medication use
Confounders
Age Complexity of the intervention Age Age
Comorbidities Expectations of patients and doctors Comorbidities Comorbidities
Socioeconomic status Socioeconomic status Socioeconomic status
Baseline scores Baseline pain Baseline pain
Gender
Duration of pain
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Table 3:The Characteristics of the included studies
Study Population
mean age
(SD)
Pain type Study
duration,
site
Study
design
Sample
size
Who is
involved
Interventions Pain scores Quality of life Other results
Bauters
(2008)
_
Chronic non-
malignant pain
9 months;
outpatient pain
center
Retrospective
study
93
Multidisciplinary
pain team
Pharmacist provision
of information,
clinical intervention,
and provision of a
specific product
95.3% of pharmacist
clinical interventions
were accepted by
physicians
Turner
(1999)
_
Medication-
induced
headache
18 weeks;
community
pharmacies
Prospective
cohort
11
Community
pharmacists,
study nurse
Pharmacists posted
flyers in the
community pharmacy
to recruit patients.
Asked them to
complete
questionnaires
Short Form Health Survey
and Henry Ford Hospital
Headache Disability
Inventory: a consistent
but not statistically
significant trend toward
improvement
1. Statistical
reduction in headache
frequency. 2.
Reduction in daily
consumption of
analgesics. 3.
Reduction in the
frequency of
medication use
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Suzuki
(2014)
44.3 (11,7);
57.8% male
Chronic pain
6 months at a
urban
academic
primary care
clinic
Prospective
cohort
33
Psychiatrist,
pharmacist,
health coaches
Initial evaluations,
buprenorphine
inductions, follow-up
visits
BPI-decreased from 5.1 (SD
=3.7) at baseline to 3.3
(SD=3.3) at 3 months and
4.5 (SD=3.7) at 6 months;
Pain disability: reduced
from 5.5 (SD =3.8) at
baseline to 2.7 (SD=2.9) at
3 months and 4.4 (SD=3.5)
at 6 months
1. 95.6% patients
accepted the
treatment and 55%
remained in the
treatment at 6
months.
Kroner
(2008)
61.6 (14.20);
45.1% male
Chronic pain
1 year in a not-
for-profit,
integrated
health system
Retrospective
cohort
47
Primary care
clinical
pharmacist,
physicians, nurse
practitioners,
physician
assistants
Used PharmDoc tool
to project Medication
Cost Avoidance
(MCA). Converted
medications for
patients and assessed
for subesquent
adverse events
1. 24 of 47 patients
persisted with new
medication. 2.
Achieved $50,000
medication cost
avoidance for 24
persistent patients.
Hay
(2006)
67.9 (8.2);
27% male
Knee pain
1 year at 15
general
practices
RCT 325
Community
pharmacist,
community
physiotherapists,
Intervention groups:
enhanced
pharmaceutical
review or community
physiotherapy control
WOMAC—Baseline to 3
months: pain scores
reduction of 0.41 (SD=3.7)
for control, and 1.59 (3.2)
for pharmacy; Intervention
1. 67%, 57%, and
52% patients satisfied
with the treatment at
3 months, 6 months,
and 12 months post-
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nurse group: advice leaflet
reinforced by
telephone call
vs control at 3 months:
mean adjusted differences
were 1.18 (0.3-2.0,
p=0.006) for pain
NRS-pharmacy review
group: baseline to 3 months:
1.34 (SD=2.5) decrease;
intervention vs controls:
0.72 (0.1-1.4, p=0.04)
randomization
respectively. 2. Self-
reported use of non-
steroidal anti-
inflammatory drugs
in the pharmacy
review group were
lower than in control
group, while the use
of analgesics was
higher (p=0.02).
Bruhn
(2013)
65.6 (12.6)
62.2% female
Chronic pain
10 months in 6
general
practices
RCT 196 pharmacists
Prescribing arm:
medication review,
prescribing,
consultation, care
plan
recommendations,
follow up; Review
arm: medication
review, care plan
recommendations;
Control arm:
CPG—Within prescribing
arm: a 8.0 (SD =16.3,
p=0.002, effect size r=0.45)
mean pain intensity
decrease and a 8.3 (0.0;23.3,
p=0.003, effect size r=0.43)
median pain disability
decrease at 6 months; within
controls: a median decrease
of 3.3 in pain Disability
(p=0.05, effect size r=0.26);
Short Form-12--only
control group showed
statistically significant
improvement in physical
component.
HADS scores
improved in within
the prescribing arm
for both depression
and
anxiety(p=0.007),
and between
arms(p=0.022 and
0.045, respectively)
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treatment as usual compared to baseline,
47.7% (p=0.003) patients in
the prescribing arm got
improvement and 38.6%
(p=0.001) in the review arm
Cunning
ham
(2009)
46.4 (14.1)
81.2% female;
Chronic non-
malignant pain
3 week
program and 6
months
outpatient at a
rehabilitation
center
Prospective
cohort
186
Multidisciplinary
team
Detailed pharmacist
interview, review of
medication bottles,
educate on
medication use,
calculate medication
cost and monitor for
withdrawal
MPI—Pain intensity:
admission to 6 months:
46.45 (SD=9.68) decreased
to 35.05 (SD=12.43)
(p<0.001); the perceived
life control and general
activity level also improved
significantly (p<0.001).
Short Form-36--
Admission to 6 months:
health perception: 42.67
(SD=22.25) increased to
60.82(SD =21.89);
physical functioning:
42.57 (SD =23.43)
improved to 69.37(SD
=21.24) (p<0.001)
1. Significant
medication cost
saving of $9.31 from
admission to
discharge.
2. Maintained
medication cost
reduction at 6
months. 3.
Decreased OTC use.
4. CES-D scores
decreased from 27.97
(SD=13) at admission
to 14.46 (SD=10.62)
at dismissal
(p<0.001).
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Dole
(2007)
60
Chronic non-
cancer pain
1 year at the
pain
management
ambulatory
clinic
Descriptive
study
1890
Pharmacist
clinicians ,
physicians, nurse
practitioners
Pharmacist clinician
patient visits, follow-
ups. write
prescriptions, also
developed
medication-refill
protocol
VAS--Significant reduction
in pain intensity (p<0.0001)
during the first 10 visits
1. Increased
consistency of the
authorization of
medication refill
process
2. Generated
$107,550 of actual
revenues and saved
health plans by over
$450,000
Wiedem
er 2007
_
Chronic non-
cancer pain
2 years at a
primary care
clinic at an
urban
academic
Veterans
hospital
Naturalistic
prospective
outcome study
335
Nurse
practitioner and
clinical
pharmacist
Pharmacist run an
Opioid Renewal
Clinic (ORC)
1. Number of urine
drug testing, opioid
treatment agreement
increased after ORC
implementation. 2.
Decline in ER visits
from 72.7% to
59.6%.
3. 84% of PCP
satisfied with service.
4. Met pharmacy
budget goals.
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Briggs
(2008)
57 (15), range 27-
86 years
Chronic pain
1 year at a
primary care
trust
A pilot study 120
Community
pharmacist, nurse
Medication review,
make treatment plan
NRS--over a 6-month
period, pain intensity on
referral were 8 (mean and
median) and on discharge
6.3 (mean) and 6 (median)
(p<0.0001)
1. Reduced need for
secondary referral.
2. 92% of patient
satisfied with the
clinic
McDer
mott
(2006)
51.4% aged 29-64,
48.6% aged 65-94;
62.1% female
Chronic pain
6 months at
one general
practice
Prospective
cohort
140 Pharmacist
Paper-based medical
record review, make
recommendations,
documentation;
interviews among
25% of the
population
CPG--19 progressed to a
more severe CPG, 25 to
milder CPG, 31 stayed the
same grade.
77% of
recommendations
were implemented
Gammai
toni
(2000) 21.6% aged ≤35,
75.7% aged 36-64;
58.1% female
Chronic pain
3 months; at a
university pain
clinic
RCT 74
PainRxperts,
pharmacist, a
nurse research
coordinator
Monitor, counselling,
documentation
PhPI--Physical and
emotional problems
interference with social
activities showed a
significant improvement in
intervention group
compared to baseline
At baseline,
participants in control
group were more
satisfied with
psychological
assessment and
treatment than
intervention group
(p<0.05); at 3
38
months, participants
in intervention group
significantly more
satisfied with
pharmacist-related
services than controls
(p≤0.013).
Read
(1998)
60.4, range 29-84;
71% female
Chronic pain
15 months at 3
medical
practices
Prospective
cohort
96 Pharmacists
Structured interview,
recommend a change
of therapy, give
advice
VAS--out of the 14 patients
available for follow up: 85
to 80 for pain relief, 80 to
70 for worst pain, 65 to 50
for average pain and 50 to
40 for pain now
Chelmin
ski
(2005)
51, ranged 27-76
years; 40% female
Chronic non-
cancer pain
3 months at a
primary care
pain
management
program
Prospective
cohort
85
A primary care
physician, a
clinical
pharmacist, a
program
assistant, a
psychiatrist, a
nurse
Structured clinical
assessment, monthly
follow-up, pain
contracts, medication
titration, monitor for
substance abuse
BPI—Baseline to 3 months:
pain intensity significantly
improved by 12% to 15%
PDI—Baseline to 3 months:
pain disability scores
improved from 47.0 to 39.3
(p<0.001)
1. Mean CESD
reduced from 24 to
18, 79% to 54% of
patients being
depressed. 3. 48% of
the patients increased
their opioid dose over
3 months, and the
mean opioid
39
equivalent increased
from 53 mg to 105
mg per day.
Neilson
(2015)
65.6 (SD=12.6) Chronic pain
10 months in 6
general
practices
Regression
analysis of cost
and effects
125 Pharmacists
Prescribing arm:
medication review,
prescribing,
consultation, plan,
follow up; Review
arm: same except
prescribing;
Control arm
Short Form-6-Dimension
(SF-6D): prescribing arm
showed slight and higher
improvement than two
other arms; review arm
and control arm also
improved compared to
baseline
1. The mean of
adjusted difference in
total cost VS TAU
from the baseline to 6
months was: 77.5
(−81.7 to 236.7)
prescribing arm, 54.4
(−103.3 to 212.1)
review arm
(p=0.0000). 2. The
mean of adjusted
difference in total
QALYs vs TAU
were: 0.0069
(−0.0091 to 0.0229)
prescribing arm,
0.0097 (−0.0054 to
0.0248) review arm
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Table 4: Risk of bias in randomized controlled trials
Study Hay et al. (2006) Bruhn et al. (2013) Gammaitoni et al. (2000)
Bias Risk Support for judgement Risk Support for judgement Risk Support for judgement
Random sequence
generation (selection bias)
* Used a computerised
random number generator
* telephone randomisation
service with a random
number allocation
* Used excel spreadsheet
randomly assign
participants
Allocation concealment
(selection bias)
* Used a sealed opaque
envelope
* telephone randomisation
with a random number
allocation, questionnaires
posted to participants
* randomization applied
Blinding of participants ** Blinding of participants is
not possible due to the
nature of the intervention
** Blinding of participants is
not possible due to the
nature of the intervention
** Blinding of participants is
not possible due to the
nature of the intervention
Blinding of outcome * Participants reported, ** No blinding ** No blinding
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assessment independent data imputed,
statistical analysis
Incomplete outcome data * Analysis was by intention
to treat
* Analysis was conducted
on intention-to-treat basis
* More than half of the data
were missing
Selective reporting ~ Not stated ~ Not stated ~ Not stated
Key ~ Unclear
*Low risk
**High risk
Table 5: Risk of bias in non-randomized studies
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Study
Chelminski
(2005)
Turner
(1999)
Cunningham
(2009)
Suzuki
(2014)
Kroner
(2008)
Outcome #
Bias
1 4 1 4 1 3 4 1 2 2 3
Confounding *** *** *** *** *** *** *** ** *** *** ***
Selection of
participants
* *** ** ** ** * * * * ~ ~
Measurement of
interventions
* * * * * * * *** *** * *
Departure from
intended interventions
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
Missing data *** *** **** **** ** * * **** ** * ***
Measurement of
outcomes
*** ** *** *** *** * * *** ** * **
Selection of the
reported result
** ** ** ** ** ** ** ** ** ** **
Overall bias *** *** **** **** *** *** *** **** *** *** ***
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Study
Briggs
(2008)
Wiedemer
(2007)
McDermott
(2006)
Read
(1998)
Outcome #
Bias
1 2 3 2 3 1 2 1
Confounding *** *** *** *** *** *** *** ***
Selection of
participants
~ ~ ~ ~ ~ ** ** **
Measurement of
interventions
** ** ** ** ** * * **
Departure from
intended interventions
~ ~ ~ ~ ~ ~ ~ ~
Missing data ** ** ** ** ** *** *** ****
Measurement of
outcomes
*** *** ** ** ** *** ** ***
Selection of the
reported result
** ** ** ** ** ** ** **
Overall bias *** *** *** *** *** *** *** ****
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Key: ~ no information available
*Low risk
**Moderate risk
***Serious risk
****Critical risk
Figure 1: Systematic review flow chart
2 additional records identified through
reviewing bibliography of included
1075 records identified
through database
682 titles and abstracts screened after
duplicates removed
646 records excluded
36 full-text articles assessed for
eligibility
14 abstracts removed, 5 full-text
articles excluded: 1 not involve
pharmacist intervention, 3
irrelevant, 1 cancer pain
17 full-text articles
included
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CHAPTER 3: RATIONALE, OBJECTIVES AND
HYPOTHESIS
3.1 Rationale: Why care?
As previously discussed, chronic pain has been persistently impacting people’s
physical and psychological functioning in all ages. Given the multi-dimensional
pathophysiology of pain, health professionals from diverse disciplines ought to be
involved. The effective use of resources to address chronic pain management remains a
major objective of health providers and policy makers. Primary care pharmacists,
especially community pharmacists with extended working hours, are the most broadly
distributed health professionals. They are located in nearly every community from cities
to rural area. Following the trend of patient-focused care, Canadian pharmacists’ scope of
practice has continued to expand in the last two decades. In Ontario, these roles include
the ability to initiate smoking/tobacco cessation, change drug
dosage/formulation/regimen, renew/extend prescription, and administer travel and
influenza vaccines.97 However, the awareness and acceptance of the expanded roles have
been low among the public.98 Little research has been done to investigate the
effectiveness of Canadian pharmacists’ new roles.
As demonstrated in the systematic review, primary care pharmacists working
independently or in multi-disciplinary teams offered patients interventions such as
medication review, consultation, care plan recommendation, patient education,
information provision, and follow-ups. The majority of the articles discussed in this paper
investigated the effect of these interventions on pain intensity and found positive results
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in reducing pain intensity. While some results were significant, others were not. Few
studies have addressed the effect of pharmacist interventions on quality of life. Only one
study generated significant improvement in physical functioning. Given the limited
evidence, more investigation needs to be done. It is also noted that most of these studies
were conducted either in the U.K. or in the U.S. There is still a lack of Canadian data on
primary care pharmacists’ effect on pain relief, particularly on quality of life in patients
with chronic pain.
Therefore, the intent of this study is to evaluate the effect of primary care pharmacist
interventions on pain scores as well as quality of life in patients with chronic pain in
Canada.
3.2 Objectives
3.2.1 Primary objective
The primary objective of this study is to examine the effectiveness of a primary care
pharmacist-driven chronic pain intervention on pain intensity of ambulatory patients with
chronic non-cancer pain.
3.2.2 Secondary objectives
The secondary objectives of this study are:
1) To evaluate the effectiveness of the intervention on pain interference.
2) To determine the effect of the intervention on the quality of life.
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3.3 Hypothesis
We hypothesize that community pharmacist interventions can reduce pain intensity
scores by 30% using the Brief Pain Inventory pain intensity subscale.79 A reduction of
30% in pain intensity is considered a clinically important difference.96 Since chronic pain
is multi-dimensional, to extensively measure the effect of the interventions, we also
hypothesize that a 2-point reduction will appear in interference subscale of BPI and a 0.2
effect size in each of the 8 subscales of Short Form-36 will be accomplished, both of
which are considered as the minimum clinical important difference.99 Effect size is
defined as the difference between the means of two groups divided by the standard
deviation, which provides the magnitude of an effect.100
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CHAPTER 4: METHODS
4.1 Study design
Before the commencement of the study, ethics clearance was obtained through the
Office of Research Ethics at the University of Waterloo (ORE #21092).
This is a prospective, pre post, pilot cohort study to be conducted in patients with
chronic pain, which is defined as pain that lasts beyond 3 months. To accomplish the
primary and secondary objectives of the study, three phrases will be designed and
completed during three months (Figure 2).
Figure 2: Study design
4.2 Population
4.2.1 Patient sample size estimation
The calculation of the sample size based on the primary research objective
hypothesis. Considering it is a two-sided hypothesis, the following formula was applied
to estimate sample size:
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Where
A: Type I error: If =0.05 then =1.96
B: Type II error: If =0.2 then =0.834
: Before intervention pain intensity score
: After intervention pain intensity score
: Variance of difference. Since this was not available, it was estimated based on the
available data from Farrar et al. study 96 using the formula Var(Xb-Xa)=Var(Xb)+
Var(Xa)-2*Cov(Xa Xb) where:
Xa: After intervention pain intensity score in Farrar et al. study
Xb: Before intervention pain intensity score in Farrar et al. study
Var: Variance
Cov: Covariance
In the calculation, reduction in pain intensity by 30% between baseline pain
intensity scores and three-month visit pain intensity scores using the BPI pain intensity
subscale and a 15% withdrawal rate was assumed. The sample size was calculated with
80% power and 95% confidence intervals. The estimated minimum sample size was 16.
4.2.2 Recruitment
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Pharmacists from an existing professional network were contacted by the researcher
through an invitation email and followed up through a telephone call or an in-person visit
as needed. The network consists of pharmacists who are affiliated with the University of
Waterloo School of Pharmacy and have indicated an interest in participating in research
projects, as well as pharmacists with an interest in chronic pain and have previously
provided consent to be contacted for pain-related research projects. For those who were
interested, a member of the research team met with the pharmacists to explain the
information letter and assess for eligibility. Informed consent was obtained from
pharmacists who met the inclusion criteria and agreed to participate. After obtaining
consent, the researcher trained the pharmacist in procedures relevant to the study and
completed a demographic survey (Appendix 3).
Inclusion Criteria for pharmacists:
 Ontario pharmacists who are registered under Part A in the Ontario College of
Pharmacists
 Practicing in community pharmacies, family health teams, or community health
centers.
Inclusion criteria for patient participants:
 Aged 18 or older
 Baseline pain intensity using BPI is 6 or higher
 Ambulatory patients
 Diagnosis of pain lasting 3 months or longer
Exclusion criteria for patient participants:
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 Patients with malignant or cancer pain
 Patients who are unable to communicate in English
 Unable to give informed consent
Patients were identified through two strategies:
1. Regular workflow. Patients who meet the eligibility criteria and seek help about pain-
related problems were identified by participating pharmacists.
2. Pharmacy review. Potential eligible patients were identified by the participating
pharmacists through their electronic records such as patients monitoring system or
disease registries.
Pharmacists identified patients through routine care, either in refilling pain-related
medications or providing education on pain-related conditions or medications. Patients
were approached by the pharmacist and were briefly introduced to the study. Pharmacists
then screened interested patients with a screening form (Appendix 4) and informed
members of the research team. A member of the research team contacted eligible patients,
provided a copy of the information letter, and explained the study in detail over the
telephone, in person, or by email. For those who agreed to participate, informed consent
was obtained. The researcher then informed pharmacists of the participation of patients.
Pharmacists assigned each patient an identification number that was blinded to the
research team and arranged visits with patients. Each pharmacist received $100 (in the
form of cash or credit card) as appreciation for their participation in the study. There was
no enrollment target for pharmacists and there was no impact on remuneration related to
enrollment targets.
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4.3 Study procedures
4.3.1 Initial visit (Figure 3)
Before the visit, pharmacists reviewed the patients’ charts to collect available
information on demographics, chronic pain & treatment history, current pain medications,
other relevant medical conditions and medications. Pharmacists then assessed the
appropriateness of pain-related medications and potential drug interactions.
During the visit, pharmacists met with patients in private sections of pharmacies or
family health teams. Pharmacists asked patients questions in regard to their complaints
and concerns on their medications and goals they wanted to achieve. Information that was
missing would be completed during the course of consultation. Pharmacists then assessed
pain score, quality of life, and adherence by administering the brief pain inventory (BPI)
(Appendix 5), and short form 36 (SF-36) (Appendix 6), respectively. Scales were either
self-administered or verbally administered by pharmacists. After obtaining above
information, pharmacists and participants reviewed the medications and discussed the
medications that were currently taken by the participants with regard to safety and
efficacy based on their conditions. During the course, patients were educated in terms of
understanding their pain and medications, potential side effects of medications, how to
respond when side effects appear, self-management, and adherence. Following the
discussion, pharmacists recommended a care plan with patients’ agreement.
After the visit, pharmacists from community pharmacies forwarded the care plan to
patients’ physicians, and discussed patients’ conditions with physicians in detail.
Pharmacists from the family health team met with the whole team (including physician
and nurses) to discuss the treatment plan. The finalized plan would then be implemented.
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Figure 3: Pharmacists’ initial visit with patients
4.3.2 Follow-up visits (Figure 4)
Patients were followed up by pharmacists approximately 2 weeks and 3 months after
the initial visit (in person or through telephone). Follow-up time frames were flexible
considering the busyness of different study sites.
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At the 2-week follow-up visit, when participants came back for reassessment of the
safety and efficacy of the therapy, the following information was documented: BPI,
MMAS-8 (Appendix 7). Changes in the therapies would be made if the current
medications were not effective or serious side effects occurred. There were slight
differences between different settings at 3-month follow-up. At community pharmacies,
pharmacists would follow up with patients alone, while at family health team,
pharmacists met with patients together with the whole team and came up with finalized
plan through discussion.
Figure 4: Pharmacists’ follow-up visits with patients
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4.4 Data collection
A data collection matrix was designed and developed for collecting data (Appendix
8). The following data were included in the matrix:
1) Demographics:
 Age, gender, educational level, income, employment status, medication coverage
2) Chronic pain and treatment history:
 Type of pain, duration
 Past medications for chronic pain, non-pharmacological treatment currently using
3) Current medications for pain
4) Other medical conditions
5) Other medications in current use
6) History of substance use
7) Brief pain inventory
8) Short form 36
9) 8-item Morisky medication adherence scale
10) Care plan recommendations
11) Recommendation acceptance
12) Pain treatment changes
 Pharmacological treatments
 Non-pharmacological treatments
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4.5 Outcome variables
 Demographics of pharmacists
--Age, gender, years in practice, educational level, practice settings, working
regime.
 Demographics of patients
--Age, gender, marital status, educational level, employment status, income,
medication coverage, type of chronic pain, pain duration.
 Pain treatment
--Past pain medications, current pain medications, current conditions other than
pain, current other medications, non-pharm interventions in current use.
 Pain score changes
--Pain score was measured using brief pain inventory.79 Pain score changes were
calculated as BPI score at follow-ups minus BPI score at baseline.
 Quality of life changes
--Quality of life was measured with short form-36.101 Quality of life changes were
calculated as SF-36 score at follow-up minus SF-36 score at baseline.
4.6 Analysis
Analysis was carried out using IBM’s Statistical Package for Social Sciences (SPSS)
(version 22.0.0.0) for the Macintosh operating system. Descriptive statistics were used to
describe patients’ baseline characteristics and interventions provided by pharmacists.
Continuous data were reported as means and standard deviations and categorical data
were reported as counts, percentages, and ranges. A paired t-test was conducted to detect
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the changes of patients’ pain scores between baseline and 3-month follow-up. One-way
repeated analysis of variance (ANOVA) was conducted to compare the effect of time on
the pain scores at baseline visit, 2-week follow-up visit, and 3-month follow-up visit.
Non-parametric paired-t test (Wilcoxon Signed Rank test) was conducted to compare
patients’ quality of life between baseline and 3-month follow-up. Subgroup analyses were
also conducted. Independent sample t-test was conducted to compare the changes in pain
scores observed based on study period (from baseline to 3-month follow-up), gender, and
adherence.
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CHAPTER 5: RESULTS
5.1. Results
5.1.1 Study participants
5.1.1.1 Pharmacist participants
Between February 2016 and June 2016, 6 pharmacists agreed to participate in the
study. Table 6 presents the demographics of pharmacist participants. The mean age of
pharmacist participants was 43.50 years, all were full-time working females and had a
BSc in Pharmacy degree, 83.3% had been practicing for more than 10 years, and 83.3%
were currently practicing in community pharmacies.
Table 6: Demographics of pharmacist participants (N=6)
Demographics N (%, where applicable)
Age (years)
Mean (SD) 43.50 (9.27)
Range 28-55
Gender
Female (%) 6 (100%)
Practice experience (years)
<5 1 (16.7%)
5-10 0 (0%)
11-15 1 (16.7%)
16-20 2 (33.3%)
>20 2 (33.3%)
Highest degree of education
BSc (Pharmacy) 6 (100%)
Primary practice settings
Family health team 1 (16.7%)
Community pharmacy 5 (83.3%)
Working regime
Full-time 6 (100%)
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5.1.1.2 Patient participants
In total, 23 patients were screened for inclusion from March 2016 to August 2016.
Of these, 13 patients were recruited. Of the 10 who were not recruited, 3 were not eligible,
and 7 did not give consent.
Figure 5: Recruitment flow chart
Of the 13 patients, 1 did not attend any visits, 12 completed the baseline visit, 10
finished the 2-week follow-up visit, and 12 completed the 3-month follow-up visit. The
average times to 2-week follow-up and 3-month follow-up were approximately 20 days
(range 14-35 days) and 122 days (range 84-155 days) respectively.
5.1.1.2.1 Demographics of patient participants
The average age was of 52.17 (SD=9.07) years, 75.0% were female, 33.3% married
or had a stable relationship and the rest were either single, widowed or divorced. Only
25.0% attended post-secondary schools and 1 had missing education data, 16.7% were
currently employed, 41.7% were unemployed and 33.3% were retired; 58.3% had an
23 patients were screened during the
recruitment period
 3 ineligible
 7 did not give
consent
13 patients were recruited
to the study
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after-tax income less than $20,000 and 16.7% were missing this information; more than
half (58.3%) were covered by Ontario Drug Benefit (ODB); the types of chronic pain
were various and the majority (91.7%) had been experiencing pain for more than 5 years.
Table 7: Baseline characteristics of patient participants (N=12)
Characteristics N (%, where applicable)
Age (years)
Mean (SD) 52.17 (9.70)
Range 41-70
Gender
Female 9 (75.0%)
Male 3 (25.0%)
Marital status
Married/Stable relationship 4 (33.3%)
Single 5 (41.7%)
Widowed 2 (16.7%)
Divorced 1 (8.3%)
Highest level of education
Elementary school 5 (41.7%)
High school 3 (25.0%)
Technical/College/University 2 (16.7%)
Graduate/Professional education 1 (8.3%)
Missing 1 (8.3%)
Employment status
Employed 2 (16.7%)
Unemployed 5 (41.7%)
Retired 4 (33.3%)
Missing 1 (8.3%)
After tax income
<$20,000 7 (58.3%)
$20,000-$80,000 3 (25.0%)
Missing 2 (16.7%)
Medication coverage
Private/Employment drug plan 4 (33.3%)
ODB 7 (58.3%)
Self-pay 3 (25.0%)
Types of chronic pain
Nociceptive 2 (16.7%)
Neuropathic 2 (16.7%)
Mixed 7 (58.3%)
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Unclear 1 (8.3%)
Duration of pain (years)
<5 1 (8.3%)
5-10 4 (33.3%)
10-20 1 (8.3%)
>20 6 (50.0%)
Numbers of other medical conditions
Mean 3.58 (1.93)
Range 0-6
5.1.1.2.2 Pain treatment history
Table 8 shows the pain medications that had been tried in the past by patient
participants. The mean number of pain medications that had been tried was 3.17
(SD=1.99) ranging from 0 to 7. Opioids and NSAIDs were the most commonly tried pain
medications, 28.2% and 23% of the total number of medications, respectively, followed
by antidepressants and anticonvulsants (17.9% and 10.3%, respectively). Alpha2-
andrenergic agonists and over-the-counter (OTC) medications were the least tried
medications (only 2.6%).
Table 8: Past medications for pain (N=12)
Number of past pain medications N (%, where applicable)
Mean 3.17 (1.99)
Range 0-7
Past pain medications
Opioid 11 (28.2%)
NSAIDs 9 (23.0%)
Antidepressant 7 (17.9%)
Anticonvulsant 4 (10.3%)
Antiemetic 3 (7.7%)
Muscle relaxant 3 (7.7%)
OTC 1 (2.6%)
Alpha2-andrenergic agonist 1 (2.6%)
62
Table 9 shows medications in current use. Similar to past pain medications, the most
common pain medications that in current use were NSAIDs and opioid, both of which
accounted for 22.0% of the total number of medications currently being used. The mean
of number of pain medications that patient participants were currently taking was 4.08
(SD=2.23) with a range from 1 to 8, while the mean of number of total medications in
current use was 11.09 (SD=2.95).
Table 9: Medications in current use (N=12)
Pain medications in current use
NSAID 11 (22.0%)
Opioid 11 (22.0%)
Antidepressant 7 (14.0%)
Anticonvulsant 6 (12.0%)
OTC (Codeine-contain product) 4 (8.0%)
OTC 2 (4.0%)
Acetaminophen 2 (4.0%)
Muscle relaxant 2 (4.0%)
Antiemetic 2 (4.0%)
Electrolyte supplement 1 (2.0%)
Alpha2-andrenergic agonist 1 (2.0%)
Opioid antagonist 1 (2.0%)
Number of pain medications in current use
Mean 4.08 (2.23)
Range 1-8
Number of total medications in current use
Mean 11.09 (2.95)
Range 3-17
Table 10 provides information on non-pharm interventions that patients were
currently taking. The average of number of non-pharm interventions that patient
participants were undergoing was 3.50 (SD=2.24) (range 0-7). There were variations
across the non-pharm interventions; the most frequently used non-pharm interventions
included exercise (66.7%), physiotherapy (53.8%), relaxation therapy (50.0%), and
chiropractor manipulations (41.7%).
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Table 10: Non-pharmacological interventions in current use (N=12)
Non-pharm in current use Number of patient in current use
Exercise 8 (66.7%)
Physiotherapy 7 (58.3%)
Relaxation therapy 6 (50.0%)
Chiropractor 5 (41.7%)
Acupuncture 4 (33.3%)
Heating therapy 2 (16.7%)
Surgery 2 (16.7%)
Massage 1 (8.3%)
Epsom salt bath 1 (8.3%)
Number of non-pharm in current use
Mean 3.50 (2.24)
Range 0-7
5.1.1.2.3 Recommendations provided by pharmacists
Table 11 presents information on recommendations provided by community
pharmacists at the three study visits. Thirty-seven recommendations were made by
community pharmacists for 10 patients; 54% of the recommendations were medication-
related and patient acceptance rate was high (range from 75% to 100%) for these. The
acceptance rate of medication-related recommendations by physician was 56.2%. Fifty
percent (50%) of the medication-related recommendations were implemented, while none
of the non-pharm interventions were implemented.
Table 11: Recommendations provided by community pharmacists at each visit (N = 10)
1st
visit
2nd
visit
3rd
visit
Patient
acceptance
Physician
acceptance
Implement
Medication-
related
Add medication
Stop medication
Change medication
Increase dose
Decrease dose
6
0
0
6
3
2
0
0
1
0
1
0
0
1
0
90% 56.2% 50%
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Referral 0 0 1 0% N/A N/A
Education 6 1 4 100% N/A N/A
Non-pharm 6 2 3 75% N/A 0%
Note: Implement rate was calculated based on the first visit and second visit; physician
acceptance rate was calculated based on prescription medications.
Table 12 shows the recommendations provided by pharmacists from family health
team at the first and second visit. The pharmacist from family health team made 17
recommendations for 2 patients at the first visit. All of the recommendations were
accepted by patients, and 44.4% were accepted and implemented by the team (including
the pharmacist).
Table 12: Recommendations provided by pharmacists from family health team at the first
and second visit (N = 2)
1st
visit
2nd
visit
Patient
acceptance
Team-based
acceptance
Implement
Medication-
related
Add medication
Stop medication
Change medication
Increase dose
Decrease dose
5
1
2
0
1
0
0
0
0
0
100% 44.4% 44.4%
Referral 1 0 100% 100% 100%
Education 6 0 100% N/A N/A
Non-pharm 1 0 100% N/A 100%
5.1.1.2.4 Patient adherence
MMAS-8 scores of 8 patients were available (Table 13). Five out of 8 patients were
highly adherent to the medications.
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Table 13: Number (%) of people whose MMAS score were high adherence, medium
adherence, or low adherence at the third visit.
3rd visit (n = 8)
High adherence (scoring 0) 5 (62.5%)
Medium adherence (scoring 1-2) 0 (0%)
Low adherence (scoring 3-8) 3 (37.5%)
5.1.1.2.5 Pain score
The average pain score of patient participants was 5.83 (SD=1.34) when admitted to
the study, which was concordant with our inclusion criteria.
5.1.1.2.5.1 The effect of time on pain score across the three visits
A one-way repeated measures ANOVA was conducted to compare the effect of time
on the pain score changes across the three visits. Tables 14 and 15 show the results from
repeated measures ANOVA. There was significant change in normal work scores across
the three visits (p = 0.022). There were no significant changes across the three visits in
terms of overall pain, worst pain in the last week, least pain in the last week, pain on
average, pain right now, and overall pain interference, general activity, mood, walking
ability, relations with other people, sleep, and enjoyment of life.
Table 14: Multivariate test (N = 10)
Wilks’ Lambda F-value p-value
Overall pain 0.715 1.596 0.261
Worst pain in the
last week
0.844 0.740 0.507
Least pain in the
last week
0.722 1.543 0.271
Pain on average 0.742 1.390 0.303
Pain right now 0.769 1.198 0.351
Overall pain
interference
0.730 1.477 0.285
General activity 0.699 1.726 0.283
Mood 0.897 0.462 0.646
Walking ability 0.574 2.966 0.109
Normal work 0.385 6.389 0.022
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Relations with
other people
0.931 0.297 0.751
Sleep 0.872 0.585 0.579
Enjoyment of life 0.903 0.430 0.665
Three paired samples t-test were used to make post hoc comparisons between groups.
There were significant differences between the first visit and second visit, and the first
visit and third visit in normal work (p=0.49, 0.30 respectively).
Table 15: Pairwise comparison in mean (SD) BPI score at the first, second, and third visits
(N = 10)
1st visit 2nd visit 3rd visit P1 P2 P3
Overall pain 6.15 (1.61) 5.53 (1.83) 5.25 (1.89) 0.789 1.000 0.289
Worst pain in the last
week
8.10 (1.79) 7.20 (1.87) 7.50 (2.22) 0.786 1.000 1.000
Least pain in the last
week
4.70 (2.16) 3.70 (2.17) 3.40 (2.17) 0.663 1.000 0.308
Pain on average 5.90 (1.29) 5.60 (1.89) 5.20 (1.75) 1.000 1.000 0.397
Pain right now 5.90 (1.97) 5.60 (2.91) 4.90 (2.51) 1.000 0.879 0.710
Overall pain
interference
6.10 (1.59) 5.64 (2.24) 5.35 (1.80) 1.000 1.000 0.447
General activity 6.50 (1.78) 5.10 (2.42) 5.50 (2.42) 0.299 1.000 0.777
Mood 5.70 (3.09) 4.80 (3.22) 5.00 (2.54) 1.000 1.000 1.000
Walking ability 6.50 (2.46) 5.70 (2.75) 5.40 (2.41) 0.411 1.000 0.307
Normal work 7.40 (1.35) 6.00 (2.26) 5.40 (2.32) 0.049 1.000 0.030
Relationships with
other people
4.50 (2.12) 5.20 (3.05) 4.50 (2.88) 1.000 1.000 1.000
Sleep 7.00 (1.49) 6.90 (1.66) 6.50 (2.07) 1.000 1.000 1.000
Enjoyment of life 5.10 (2.51) 5.80 (2.78) 5.15 (2.21) 1.000 1.000 1.000
Note: p1 refers to the p-value between the first and second visit; p2 refers to the p-value
between the second and third visit; p3 refers to the p-value between the first and third visit.
5.1.1.2.5.2 Comparison between the first and third visit on pain score
A paired t-test was used to compare the difference in BPI scores between the first
and third visits. There were trends toward improvement in overall pain, worst pain in the
last week, least pain in the last week, pain on average, pain right now, overall pain
interference, general activity, mood, walking ability, normal work, and sleep when
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comparing baseline with 3-month follow-up, but none of the improvements were
significant.
Table 16: Mean (SD) BPI score at the first and third visit, and the improvement (N = 12)
1st visit 3rd visit Improvement P-value
Overall pain 5.99 (1.52) 5.48 (1.96) 8.51% 0.383
Worst pain in the last
week
8.17 (1.64) 7.83 (2.17) 4.16% 0.570
Least pain in the last
week
4.25 (2.22) 3.67 (2.23) 13.65% 0.482
Pain on average 5.83 (1.34) 5.42 (1.78) 7.03% 0.459
Pain right now 5.67 (1.87) 5.17 (2.44) 8.82% 0.477
Overall pain
interference
6.07 (1.48) 5.84 (1.99) 3.79% 0.685
General activity 6.55 (1.69) 5.91 (2.66) 9.77% 0.463
Mood 5.67 (2.87) 5.42 (2.50) 4.41% 0.718
Walking ability 6.00 (2.34) 6.00 (2.63) 0% 1.000
Normal work 7.17 (1.85) 6.00 (2.56) 16.32% 0.171
Relations with other
people
4.17 (2.08) 4.67 (3.26) -11.99% 0.563
Sleep 7.00 (1.41) 6.75 (2.01) 3.57% 0.633
Enjoyment of life 5.50 (2.47) 5.96 (2.75) -8.36% 0.605
5.1.1.2.5.3 Subgroup analysis
5.1.1.2.5.3.1 Comparison between different study periods at the third visit
Independent sample t-test was conducted to compare the differences on pain score
changes at the third visit between groups who finished study within 4 months and beyond
4 months. The analysis showed that there were significant differences on general activity
and enjoyment of life between the two groups (p=0.048 and 0.048, respectively). No
significant results were found in other aspects of BPI score.
Table 17: Mean of BPI score changes (1st VS 3rd) (SD) in groups of study period<4 months
and study period>4 months (N = 12)
Study period<4
(n = 5)
Study period >4
(n = 7)
p-value
Overall pain -1.17 (1.74) -0.04 (2.06) 0.341
Worst pain in the last -0.60 (1.52) -0.14 (2.34) 0.711
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week
Least pain in the last
week
-0.60 (1.14) -0.57 (3.64) 0.987
Pain on average -1.60 (1.52) 0.43 (1.72) 0.061
Pain right now -1.40 (2.70) 0.14 (2.04) 0.284
Overall pain interference -0.76 (2.57) 0.16 (1.21) 0.417
General activity -2.75 (3.10) 0.57 (1.81) 0.048
Mood -0.80 (2.49) 0.14 (2.34) 0.518
Walking ability -1.20 (3.27) 0.86 (2.73) 0.263
Normal work -0.80 (3.56) 0.00 (2.08) 0.716
Relations with other
people
1.20 (3.96) 0.00 (2.08) 0.507
Sleep -0.40 (1.82) -0.14 (1.86) 0.817
Enjoyment of life -1.50 (2.65) 1.85 (2.48) 0.048
5.1.1.2.5.3.2 Comparison between females and males at the third visit
Independent sample t-test was conducted to compare the differences on pain score
changes at the third visit between female patients and male patients. The analysis showed
that female patients had significant higher normal work score reduction than male
patients (p=0.032). No significant results were found in other aspects of BPI scores.
Table 18: Mean of BPI score changes (1st VS 3rd) (SD) in female and male (N = 12)
Female (N=9) Male (N=3) p-value
Overall pain -1.04 (1.73) 1.08 (1.89) 0.102
Worst pain in the last week -0.67 (2.18) 0.67 (0.58) 0.333
Least pain in the last week -1.33 (2.40) 1.67 (3.06) 0.107
Pain on average -0.89 (1.27) 1.00 (3.00) 0.138
Pain right now -1.00 (2.35) 1.00 (2.00) 0.218
Overall pain interference -0.64 (1.54) 1.02 (2.49) 0.191
General activity -0.89 (2.76) 0.50 (3.53) 0.549
Mood -0.22 (1.79) -0.33 (4.16) 0.947
Walking ability -0.78 (3.03) 2.33 (1.53) 0.126
Normal work -2.11 (2.03) 1.67 (3.05) 0.032
Relations with other people 0.22 (1.72) 1.33 (5.77) 0.591
Sleep -0.22 (1.39) -0.33 (3.05) 0.930
Enjoyment of life 0.06 (3.30) 1.67 (1.53) 0.444
5.1.1.2.5.3.3 Comparison between high adherence group and low adherence group
at the third visit
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Independent sample t-test was conducted to compare the differences on pain score
changes at the third visit between high adherence and low adherence groups. Results
showed there was no significant difference between the two groups.
Table 19: Mean of BPI score changes (1st VS 3rd) (SD) in high adherence group and low
adherence group (N = 8)
High adherence
(n = 5)
Low adherence
(n = 3)
P-value
Overall pain -1.00 (1.70) -1.20 (2.52) 0.896
Worst pain in the last
week
-1.60 (2.19) 0.33 (2.08) 0.265
Least pain in the last week -1.20 (3.35) -0.67 (1.53) 0.808
Pain on average -0.80 (0.84) -1.67 (2.08) 0.424
Pain right now -0.40 (1.95) -2.00 (3.46) 0.424
Overall pain interference 0.24 (2.05)) -1.57 (1.96) 0.267
General activity -0.50 (2.08) -2.67 (3.79) 0.371
Mood 0.60 (1.82) -1.33 (2.52) 0.249
Walking ability -0.40 (2.88) -2.33 (2.08) 0.355
Normal work -1.00 (3.67) -3.33 (1.53) 0.346
Relations with other
people
1.20 (3.96) 1.00 (2.64) 0.941
Sleep 0.20 (1.30) -1.00 (1.73) 0.304
Enjoyment of life 1.20 (3.77) -1.50 (3.12) 0.340
5.1.1.2.6 Quality of life
The Wilcoxon signed-ranks test indicated there was no significant difference in SF-
36 score when comparing baseline with 3-month follow-up.
Table 20: Mean (SD) SF-36 at the first and third visit (N = 11)
1st visit 3rd visit P-value
Physical functioning 42.07 (20.26) 39.14 (22.27) 0.440
Role limitations due to
physical health
18.94 (20.10) 46.22 (45.85) 0.057
Role limitations due to
emotional problems
44.70 (43.19) 42.42 (39.69) 0.833
Energy/fatigue 35.00 (21.91) 32.73 (17.08) 0.721
Emotional well-being 61.09 (24.07) 62.91 (23.87) 0.878
Social functioning 54.55 (21.85) 63.64 (28.20) 0.380
Pain 31.36 (13.48) 35.45 (15.84) 0.206
General health 43.98 (15.94) 45.00 (16.73) 0.725
70
CHAPTER 6: OVERALL DISCUSSIONS AND
CONCLUSIONS
6.1 Discussions
6.1.1 Summary of results
This three-month prospective pilot study investigated the effectiveness of
interventions offered by pharmacists from primary care settings on pain intensity, pain
interference and quality of life among patients with chronic pain. Interventions included
patient assessments, medication reviews, care plan recommendations, and patient
education. Findings at the 3 months follow-up indicated that pharmacists’ interventions
had no significant effect on pain or quality of life scores in patients suffering from
chronic pain, except for the significant difference detected on the pain interference with
normal work from baseline and 2 weeks follow-up. The research hypothesis of a 30%
reduction in pain intensity was not proven. Nevertheless, there were trends toward
improvement in many aspects of BPI scale except for pain interference with walking
ability, relations with other people, and enjoyment of life.
6.1.2 Pain score
Although it has been established that pain is a multi-faceted disorder, pain intensity
is still considered as the main outcome in pain management. Our study reported an
improvement in pain intensity of 4.16% to 13.65% (including overall pain, worst pain in
the last week, least pain in the last week, pain on average, and pain right now). Our
results from BPI pain interference subscale found improvements on overall pain
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interference, pain interference with general activity, mood, normal work, and sleep, but
worse on pain interference with relations with other people and enjoyment of life. These
findings are consistent with previous studies that investigated the effect of pharmacist
interventions on larger population of chronic pain patients. For instance, one study
reported a significant reduction of 21.25% in pain intensity at 6-month post-
intervention.76 Another study found a reduction of 12.0% to 15.0% (p<0.05) in pain
intensity using BPI, and improvements of 16% and 37.0% (p<0.05) in pain disability
using PDI and depression using CESD respectively. 64
Although this study failed to detect any significant improvement in pain scores at
the three-months follow-up, time factor was found to have a positive significant effect on
pain that interferes with normal work, including housework and outdoor activities.
Several factors could have contributed to the lack of any significant data in our study.
One of the major factors could be the small sample size of participants enrolled in this
study. Small sample size usually affects the ability to generate enough power to detect
any differences, if one exists. Several studies that detected significant effect on
pharmacists’ intervention in chronic pain management were conducted on a larger
population.64,66,69,70 According to our earlier sample size calculation, a total of 13
participants were required to complete the study at three time intervals (baseline, two-
weeks, and three months). However, we were only able to include a total of 12
participants in the analysis.
The lack in detecting a noteworthy improvement could also be related to the
extended follow-up period. We presumed that if patients spent shorter time employing
pharmacists’ recommendations, more meaningful effects could be detected. In an attempt
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to verify this perception, we assessed the impact of study period on BPI scores at the 3
months’ follow-up. We recorded that patients who completed their 3 months follow up on
time achieved better outcome in pain interference with their general activity and
enjoyment of life compared to those who did not complete their 3 months follow up on
time. Overall, the average score of change in “pain on average” scores at 3 months’
follow-up was about -1.60. This change in the average pain score is close to -1.74 which
considered a clinically significant change on a 0-10 rating scale according to Farrar et
al.96
The presumption related to the duration of follow-up is also consistent with findings
from a British study conducted by Hay et al. who examined the effectiveness of
medication review by community pharmacists on patients with chronic knee pain. Hay
and colleagues detected a significant reduction in pain scores at 3-month interval,
however this effect was not sustainable at both 6 and 12-month intervals. The reason
behind the unsustainable effectiveness of pharmacist intervention is still unclear, but Hay
et al. suggested that in order to obtain a sustainable effect, pharmacists’ input in pain
management should be maintained over a long-term period.71
This could also be due to the paucity of standardized collaboration model between
physician and pharmacist, especially in chronic pain management. Physicians seem to be
reluctant in accepting and implementing pharmacists’ recommendations, which may fade
the effect across time. In our study, only a little more than half of physicians (56.2%)
accepted the medication-related recommendations provided by community pharmacists
and only half of these recommendations were employed. This could considerably affect
the impact of pharmacists’ intervention.
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Another explanation could be related to the low medication adherence. Medication
adherence is an important predictor of effectiveness of medication-related treatments
especially in managing chronic conditions. Only 8 patients’ MMAS-8 were available at 3
months. Of those only 62.5% showed adherence to recommended medications. This
indicates that our modest outcome could have been affected by low adherence.
Evidence shows that reaction to pain is subjective and can be influenced by
psychological factors. Pharmacists participating in our study reported that patients with
declined pain control had enduring family problems, while those who showed better pain
control were unperturbed. However, it is not possible to examine this variable with our
small sample size.
It was surprising to find that female participants were significantly more likely to
report a reduction in the pain that interferes with standard work compared to males.
Although studies showed that women are more sensitive to pain than men, no consistent
findings regarding the impact of gender on responses to pharmacological and non-
pharmacological treatment have been documented.102
6.1.3 Quality of life
Although the quality of life scale is one of the important indicators in pain
management, it still hasn't been adequately investigated. Inconsistent results on quality of
life, when investigated, were also found in previous studies. For example, Cunningham et
al. evaluated pain in a multidisciplinary rehabilitation program which involved 178
patients and found significant improvement in health perception and physical functioning
of SF-36 at 6-month post-treatment.66 A British study done by Bruhn et al. did not find
any significant results in SF-12 in both pharmacist prescribing arm or pharmacist review
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arm with about 45 patients in each arm.70 Turner et al. found a consistent but not
significant improvement at follow-up in 10 patients.75
Our study couldn’t identify any significant results for both BPI and SF-36 scores.
However, we detected some discrepancies between pain interference scores between both
scales. For example, we reported an improvement in pain control that interferes with the
general activity by 9.77% and normal work by 16.32 % in BPI at three months’ follow-up.
On the other hand, a decline in physical functioning scores was detected by the SF-36
scale. Also, pain that interferes with a relationship with other individuals showed a
reduction of 12.0% with the BPI whereas social functioning assessed by SF-36 showed
improvement of 16.7%. The reason behind this contrariety could be due to the different
ways each scale is interpreted by the patient when completing it.
6.1.4 Recommendations provided by pharmacists
The primary care pharmacists included in our study were from different settings.
Pharmacists were either working at a community pharmacy, or at a Family Health Team.
This likely influenced their practice approach. For example, the pharmacist working at a
community pharmacy usually arranged for a one-on-one meeting with patients, then
forward their treatment plan to physicians with no direct face-to-face contact with the
physician. However, at the family health centre, pharmacist usually met with patients to
perform a comprehensive assessment of their condition before coming up with a care
plan. They then met with the inter-disciplinary team to discuss the plan. Therefore, the
acceptance rate was expected to considerably differ between both settings. Additionally,
the management plan is a team-based decision, which makes it difficult to assess the
acceptance rate of the pharmacist interventions by physician at the family health team.
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This might justify the low acceptance rate in our study, however it is still inconsistent
with findings from other studies. For example, Bauters et al. reported an acceptance rate
of 95.3% for medication management plan provided by pharmacists in a multidisciplinary
pain management program. In addition, one British study reported a 100% acceptance
rate of the pharmacists’ pain intervention plan by physicians and an 84.4% acceptance
rate in another. However, these high acceptance rates may depend on the ability of the
British pharmacists to prescribe. Having the authority to implement recommendations
may have influenced the acceptance and implementation rates found in these studies.
It is noteworthy that the role of Canadian pharmacists in most part of Canada is still
limited with no prescribing authority. Although pharmacists’ extended care in medication
management had been established for decades, the awareness of pharmacists’ extended
role continues to be limited by both physicians’ and pharmacists. Pharmacological
treatment of pain is complex and sometimes problematic given the different dimensions
of its pathophysiology and etiology. Therefore, the multidisciplinary collaboration and
shared decisions are strongly needed for better pain management.
6.1.5 Clinical implications and future directions
This pilot study shed some light on the important role of primary care pharmacists in
chronic pain management. Pharmacists can effectively contribute to pain management.
Although, our results were not significant but promising, it is difficult to generalize our
findings due to our small sample size. Further studies with larger sample size are needed
to comprehensively investigate the effectiveness of pharmacists’ contribution to pain
management as well as cost-effectiveness aspect of the contribution.
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6.1.6 Strengths
To our knowledge, this is the first study to assess the effectiveness of interventions
provided by pharmacists in pain management in Canada. The study is the first in covering
different primary care. Our study presented real-life practice skills with no previous
training offered to pharmacists.
6.1.7 Limitations
Like all studies, our study had some limitations. The main limitation is the small
sample size. It affected our conclusions from pain and quality of life scales. In addition,
we were not able to adjust for patients’ characteristics, which might have confounded
some of the results, especially those related to subgroup analyses. It was our aim to
investigate the impact of involving pharmacists from different primary care settings on
patients’ health outcomes, but this study was not powerful enough to explore this impact.
Although our intention was to mimic real-life practice skills, enrolling pharmacists with
diverse level of knowledge and experience might have affected the impact of the
intervention.
6.2. CONCLUSIONS
Primary care pharmacists are widely allocated and readily accessible, which gives
them a natural advantage in patients’ care.
This study showed that interventions of primary care pharmacists had no significant
effect on pain or quality of life in patients with chronic pain. However, positive trends
towards reducing pain intensity and pain interference with patients’ general activity,
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mood, normal work, and sleep were observed. Reasons for why pharmacist interventions
did not significantly improve patient outcomes could be attributed to small sample size,
low implementation rate of pharmacist recommendations by physicians, low patient
adherence, or extended study period.
Pharmacists’ intervention in pain management is an effective use of resources for
better health outcomes. However, for pharmacists’ intervention plan to work effectively,
collaboration between physicians and pharmacists based on mutual trust and shared
decision-making is required.
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Purpose of the research: To evaluate the effect of pharmacist-provided interventions on patients
with chronic pain. This pilot study, conducted as Mo Chen’s Master’s thesis project, will be
conducted in local community pharmacies, family health team facilities, and community health
centres.
Procedures: Pharmacists from community pharmacies, family health teams, or community health
centers will be invited to join this project.
If you agree to participate, you will be trained in study-relevant procedures and asked to complete
a demographic survey. You will be asked to recruit patients aged 18 and older and whose pain has
lasted at least 3 months and whose average pain intensity scores are 6 or higher as determined by
the Brief Pain Inventory (BPI). Patients who are unable to communicate in English or who suffer
malignant or cancer pain or are unable to give informed consent will not be eligible to participate.
Eligible patients can be identified through regular workflow or by reviewing patient records.
When a suitable patient is on-site, you will approach them and briefly introduce the study,
specifying that the services offered are within the scope of usual care. If they are interested, you
will ask their permission to be screened for eligibility by helping them to determine their average
pain score using the BPI. If ineligible, you will thank the patient and provide the usual care. If
eligible and interested, you will ask their permission to be contacted by a member of the research
team. If they agree, a member of the research team will contact them to explain the study in detail,
obtain consent and arrange for an initial visit with you. At the initial visit, you will collect patient
demographic data, administer a baseline assessment and medication review, design and
implement a customized patient care plan, and provide any education as needed. You will share
documentation with the patient's physician. You will do the assessment in a patient counseling
room or a private examination room in your practicing site. Follow-up visits will be scheduled
two weeks and three months after the initial visit. The exact timing, duration and type of follow-
up visit (clinic visit or telephone visit) will be determined by you and patient care needs. You will
be asked to complete patient-related study data at each of these visits. A member of our research
team will collect the data from you. The following provides additional detail.
Initial visit (approximately 1 one hour)
 You will ask each patient questions about their demographics (i.e. age), their chronic pain
and treatment history, their pain medication use, other medical conditions and
medications, and their substance use history.
 You will assess patients’ general health and functioning, experience of pain, concerns
about their medications, and medication adherence using standardized tools.
 You may then make recommendations to help improve their therapy, and discuss these
with the patient and their doctor, as needed, to decide on an agreed upon plan.
Reaching the stage where a plan has been agreed upon and implemented may take some days,
depending on the availability of the patient and the doctor. You will follow-up with the patient as
needed according to the plan. For the purposes of this study, we ask that you meet with the patient
two weeks and three months after the initial visit for formal follow-up and documentation.
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Second visit—at two weeks (approximately 30 minutes)
 You will ask the patient questions about their medication use and any changes in their
treatments since the last visit.
 You will assess patients’ general health and functioning, experience of pain, concerns
about their medications, and medication adherence with standardized tools as above.
Final visit—at three months (approximately 1 hour)
 You will again ask the patient questions about their medication use and any changes in
their medical treatments since the last visit.
 You will assess their general health and functioning, experience of pain, concerns about
their medications, and medication adherence with standardized tools as above.
Possible risks or discomfort: There are no anticipated increased risks to you in implementing
the clinical service since it is within your scope of practice. The study is intended to provide
structure to this service to collect data on its value.
Safeguards: As per usual care, patients are given detailed education during the session with you
and their understanding is assessed. However, in the event they misunderstand, patients will be
informed that you are available during business hours for them to call or come in to see. Outside
of these hours, patients will be advised to go to an after-hours clinic or to an emergency room, if
urgent.
Possible benefits: There is no direct benefit to you to participate in this study. Generally, you
will be helping to demonstrate the potential value of pharmacists to patients with chronic pain in
community settings.
Remuneration: You will receive $100 (in the form of cash credit card) as appreciation for your
participation in the study. The amount received is taxable. It is your responsibility to report this
amount for income tax purposes.
Confidentiality: All information obtained in the study will be kept confidential. No information
identifying you or your practice/pharmacy will be associated with the data collection forms. All
pharmacist participants will be assigned a study number that will replace their names. All files
will be maintained on a secure server and password protected laptop encrypted with SecureDoc
Enterprise by WinMagic in the School of Pharmacy, University of Waterloo. Access to all
records will be limited to authorized individuals on the research team. University of Waterloo
policies for use of restricted information are being followed. Once analysis is completed, all
records of study will be stored for 3 years, then they will be destroyed, or erased. If under any
circumstance the data is shared, only the anonymized dataset will be shared. The results of the
study may be published for scientific purposes but will not include your name or any identifying
information. The security plan for patients is explained in the patient letter, please refer to the
patient information letter.
Voluntary participation in the study: Participation in this study is voluntary. You may decline
to answer any question. You can withdraw your participation at any time with no penalty by
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notifying Mo Chen at the email address and phone number below. The study is voluntary for
patients as well, and they can withdraw at any time with no penalty by notifying Mo Chen at the
email address and phone number below.
Since this study is taking place in your practice setting, in the event that you wish to participate,
we request that your manager or supervisor acknowledge your participation by signing at the end
of this form as well.
Questions and Contacts: Should you have any questions about the study, please contact Mo
Chen at m243chen@uwaterloo.ca or 1 226 978 5465.
This project has been reviewed by, and received ethics clearance, through a University of
Waterloo Research Ethics Committee. I was informed that if I have any comments or concerns
resulting from my participation in this study, I may contact Dr. Maureen Nummelin, Director
Ethics Officer, at 519-888-4567, ext. 36005 or maureen.nummelin@uwaterloo.ca.
CONSENT FORM
By signing this consent form, you are not waiving your legal rights, or releasing the
investigator(s), or involved institutions from their legal and professional responsibilities.
I have read the information presented in the information letter about a study being conducted by
Feng Chang, PharmD, Tejal Patel, PharmD, and M.Sc. candidate Mo Chen, School of Pharmacy,
at the University of Waterloo. I have had the opportunity to ask any questions related to this study,
to receive satisfactory answers to my questions, and any additional details I wanted. I am aware
that I may withdraw from the study without penalty at any time by advising there searchers of this
decision.
I have been given a copy of this informed consent and information sheet to keep for my own
records. If I have any further questions I understand that I can contact a student Principal
Investigator Mo Chen at m243chen@uwaterloo.ca or 1 226 978 5465.
With full knowledge of all foregoing, I agree, of my own free will, to participate in this study.
Print name: ____________________
Signature: Date:
Witness: Date:
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Purpose of the research: To evaluate the effect of pharmacist-provided interventions on patients
with chronic pain. This pilot study, conducted as Mo Chen’s Master’s thesis project, will be
conducted in local community pharmacies, family health team facilities, and community health
centres.
Procedures: Pharmacists from community pharmacies, family health teams, or community health
centres will be invited to participate in this project. They will assist with recruiting consenting
patients 18 years of age, or older whose pain has lasted 3 months or more and whose average pain
intensity scores are 6 or higher using the Brief Pain Inventory (BPI) to participate in this study
with the aim to improve their pain management.
Patients will be approached by the pharmacist, briefly introduced to the study, and assured that
the interventions employed in the study are within usual care guidelines. If interested, patients
will be screened for eligibility by the pharmacist, who will help them determine their pain scores
using one question from the BPI. Based on our inclusion criteria, pain scores less than 6 will
make the individual ineligible for inclusion in the study, but the normal standard of care will
continue.
If the score is 6 or higher, your pharmacist will reaffirm your interest in the study and obtain
permission for research staff to contact you directly. Participation is voluntary and declining the
invitation will not affect current or future care by the pharmacist. After you have enrolled in the
study, the pharmacist will administer a comprehensive medication review and assessment using
standardized tools, during which your treatment goals will be set up. These goals are set based on
joint discussion between the pharmacist and you and will be communicated to the physician via
the consultative letter. Based on the information obtained from the medication review and
assessment, the pharmacist may have specific suggestions. The assessment will be conducted in a
patient counseling room or a private examination room on-site at your pharmacy. Your
documentation (the results of the assessment and medication review) will be shared with your
physician. Your pharmacist will then plan to follow up with you to monitor progress in achieving
your goals for pain control. Follow-up visits will be scheduled at 2 weeks and 3 months after the
initial visit. At each visit, you will be asked questions about your health and medications. Any
information collected by your pharmacist will be labelled with an ID instead of your name. Your
information will not be shared outside of the research team.
Initial visit (approximately 1 one hour)
 Your pharmacist will ask you questions about your age, sex, education, chronic pain and
treatment history, pain medication use, other medical conditions and medications,
substance use history, and medication adherence.
 Your pharmacist will assess your general health and functioning, your experience of pain,
your concerns about your medications, and medication adherence with standardized tools.
 Your pharmacist may make some recommendations to help improve your therapy. The
recommendations will be discussed with you and your doctor to design an agreeable plan.
Reaching the stage where a plan has been agreed upon and implemented may take some days,
depending on the availability of you and your doctor. Your pharmacist will follow-up with you as
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needed to help you with the plan. As part of this study, we ask that you meet with the pharmacist
two weeks and three months after the initial visit for formal follow-up and documentation.
Second visit—at two weeks (approximately 30 minutes)
 Your pharmacist will ask you questions about your medication use and any changes in
your treatments since the last visit.
 Your pharmacist will assess your general health and functioning, your experience of pain,
your concerns about your medications, medication adherence with standardized tools.
Final visit—at three months (approximately 1 hour)
 Your pharmacist will again ask you questions about your medication use and any changes
in your medical treatments since the last visit.
 Your pharmacist will assess your general health and functioning, your experience of pain,
your concerns about your medications, medication adherence with standardized tools.
Possible risks or discomfort: There are no known or anticipated risks associated with
participation in this study. The care provided is within the scope of practice for pharmacists.
More generally, contemplating changes to your pain treatment might cause you some anxiety, or
discomfort. To help prevent or reduce this, your pharmacist will provide support as you make
these decisions. Your pharmacist will be available during business hours for you to call or come
in to see. Outside of these hours, you will be advised to go to an after-hours clinic or to an
emergency room, if urgent.
Possible benefits: There are no direct benefits to you by participating in this study. There is the
possibility that you may have improvements associated with your chronic pain management.
Confidentiality: There are always concerns about privacy when you provide information about
yourself, your pain, and pain medications. Information obtained in the study will be kept
confidential. You will be assigned a code number that will be used to label all information, in
place of your name. The research team at the University of Waterloo will not have access any of
your identifiable information. Data collected for the purposes of this study will be maintained in a
secured locked cabinet and/or password protected laptop encrypted with SecureDoc Enterprise by
WinMagic at the School of Pharmacy, University of Waterloo. Access to all records will be
limited to authorized individuals on the research team. University of Waterloo policies for use of
restricted information are being followed. Once analysis is completed, all records kept by
University of Waterloo researchers will be stored for 3 years, then they will be destroyed, or
erased. All of the data will be summarized and no individual could be identified from these
summarized results. If under any circumstance the data is shared, only the anonymized dataset
will be shared. The results of the study may be published for scientific purposes but will include
group information and will not give your name or include information that will identify you.
Voluntary participation in the study: Participation in this study is voluntary. You may decline
to answer any question you do not want to respond to and you can withdraw your participation at
any time by notifying Mo Chen at the email address and phone number below. If you choose not
to participate or you decide to withdraw at any time, your care will not be affected. The
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pharmacist will not be upset if you choose not to participate. Regardless of your participation,
your pharmacist will provide care as usual.
Questions and Contacts: Should you have any questions about the study, or would like
additional information to assist you in reaching a decision about participation, please contact Mo
Chen at m243chen@uwaterloo.ca or 1 226 978 5465.
This project has been reviewed by, and received ethics clearance, through a University of
Waterloo Research Ethics Committee. I was informed that if I have any comments or concerns
resulting from my participation in this study, I may contact Dr. Maureen Nummelin, Director
Ethics Officer, at 519-888-4567, ext. 36005 or maureen.nummelin@uwaterloo.ca.
CONSENT FORM
By signing this consent form, you are not waiving your legal rights, or releasing the
investigator(s), or involved institutions from their legal and professional responsibilities.
I have read the information presented in the information letter about a study being conducted by
Feng Chang, PharmD, Tejal Patel, PharmD and M.Sc. candidate Mo Chen, of the School of
Pharmacy, at the University of Waterloo. I have had the opportunity to ask any questions related
to this study, to receive satisfactory answers to my questions, and any additional details I wanted.
I am aware that I may withdraw from the study without penalty at any time by advising the
researchers of this decision.
I have been given a copy of this informed consent and information sheet to keep for my own
records. If I have any further questions I understand that I can contact the student Mo Chen at
m243chen@uwaterloo.ca or 12269785465.
With full knowledge of all foregoing, I agree, of my own free will, to participate in the study
including the screening part of this study.
Print name: _______________________
Signature: Date:
Witness: Date:
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APPENDIX 3: Pharmacist demographic survey
Pharmacist and Pharmacy Characteristics
Participant ID: Date: / /
Age (in years): Gender (specify):
Practice experience (in years)
1. ≤5 2. 5-10 3. 11-15 4. 16-20 5. >20
Highest degree of education:
1. BSc (Pharmacy) 2. MSc 3. PharmD 4. Other (specify):
Primary practice setting:
1. Family health team 2. Community pharmacy 3. Community health centre
Working regime:
1. Full-time 2. Part-time 3. Other (specify):
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APPENDIX 4: Patient screening form
□ Aged 18 years or older
□ Average pain intensity score out of BPI is 6 or higher
□ Ambulatory
□ Pain lasting 3 months or longer
□ Diagnosed with malignant or cancer pain
□ English speaking
□ Unable to give informed consent
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APPENDIX 5: Brief Pain Inventory
Hunter Integrated Pain Service
Brief Pain Inventory
Dec 2006
Reproduced with acknowledgement of the Pain Research Group
The University of Texas MD Anderson Cancer Center, USA
Participant ID#: ________________
Date: ________________________
1．On the diagram, shade in the areas where you feel pain. Put an X on the area that
hurts most.
2．Please rate your pain by circling the one number that best describes your pain at its
worst in the last week.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
3．Please rate your pain by circling the one number that best describes your pain at its
least in the last week.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
107
4．Please rate your pain by circling the one number that best describes your pain on
average.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
5．Please rate your pain by circling the one number that tells how much pain you have
right now.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
6．What treatments or medications are you receiving for your pain?
_______________________________________________________________________
_______________________________________________________________________
7．In the last week, how much relief have pain treatments or medications provided?
Please circle the one percentage that
best shows how much relief you have received.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No relief Complete relief
8． Circle the one number that describes how, during the past week, pain has interfered
with your:
a. General activity
0 1 2 3 4 5 6 7 8 9 10
Does not interfere Completely interferes
b. Mood
0 1 2 3 4 5 6 7 8 9 10
c. Walking ability
0 1 2 3 4 5 6 7 8 9 10
d. Normal work (includes both outside the home and housework)
0 1 2 3 4 5 6 7 8 9 10
e. Relations with other people
108
0 1 2 3 4 5 6 7 8 9 10
f. Sleep
0 1 2 3 4 5 6 7 8 9 10
g. Enjoyment of life
0 1 2 3 4 5 6 7 8 9 10
Does not interfere Completely interferes
Brief Pain Inventory Scoring Instructions
1. Pain Severity Score
This is calculated by adding the scores for questions 2, 3, 4 and 5 and then dividing by 4.
This gives a severity score out of 10.
2. Pain Interference Score
This is calculated by adding the scores for questions 8a, b, c, d, e, f and g and then
dividing by 7. This gives an interference score out of 10.
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APPENDIX 6: Short Form-36
Participant ID# : Ref. Dr : Data:
Age: _______ Gender: M / F
Please answer the 36 questions of the Health Survey completely, honestly, and without
interruptions.
GENERAL HEALTH:
In general, would you say your health is:
□Excellent □Very Good □Good □Fair □Poor
Compared to one year ago, how would you rate your health in general now?
□Much better now than one year ago
□Somewhat better now than one year ago
□About the same
□Somewhat worse now than one year ago
□Much worse than one year ago
LIMITATIONS OF ACTIVITIES:
The following items are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
Vigorous activities, such as running, lifting heavy objects, participating in strenuous
sports.
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or
playing golf
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Lifting or carrying groceries
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Climbing several flights of stairs
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
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Climbing one flight of stairs
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Bending, kneeling, or stooping
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Walking more than a mile
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Walking several blocks
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Walking one block
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
Bathing or dressing yourself
□Yes, Limited a lot □Yes, Limited a Little □No, Not Limited at all
PHYSICAL HEALTH PROBLEMS:
During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical health?
Cut down the amount of time you spent on work or other activities
□Yes □No
Accomplished less than you would like
□Yes □No
Were limited in the kind of work or other activities
□Yes □No
Had difficulty performing the work or other activities (for example, it took extra
effort)
□Yes □No
EMOTIONAL HEALTH PROBLEMS:
During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of any emotional problems (such as feeling
depressed or anxious)?
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Cut down the amount of time you spent on work or other activities
□Yes □No
Accomplished less than you would like
□Yes □No
Didn't do work or other activities as carefully as usual
□Yes □No
SOCIAL ACTIVITIES:
Emotional problems interfered with your normal social activities with family,
friends, neighbors, or groups?
□Not at all □Slightly □Moderately □Severe □Very Severe
PAIN:
How much bodily pain have you had during the past 4 weeks?
□None □Very Mild □Mild □Moderate □Severe □Very Severe
During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework)?
□Not at all □A little bit □Moderately □Quite a bit □Extremely
ENERGY AND EMOTIONS:
These questions are about how you feel and how things have been with you during the
last 4 weeks. For each question, please give the answer that comes closest to the way you
have been feeling.
Did you feel full of pep?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
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Have you been a very nervous person?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Have you felt so down in the dumps that nothing could cheer you up?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Have you felt calm and peaceful?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Did you have a lot of energy?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Have you felt downhearted and blue?
□All of the time
□Most of the time
□A good Bit of the Time
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□Some of the time
□A little bit of the time
□None of the Time
Did you feel worn out?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Have you been a happy person?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
Did you feel tired?
□All of the time
□Most of the time
□A good Bit of the Time
□Some of the time
□A little bit of the time
□None of the Time
SOCIAL ACTIVITIES:
During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with friends,
relatives, etc.)?
□All of the time
□Most of the time
□Some of the time
□A little bit of the time
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□None of the Time
GENERAL HEALTH:
How true or false is each of the following statements for you?
I seem to get sick a little easier than other people
□Definitely true □Mostly true □Don't know □Mostly false □Definitely false
I am as healthy as anybody I know
□Definitely true □Mostly true □Don't know □Mostly false □Definitely false
I expect my health to get worse
□Definitely true □Mostly true □Don't know □Mostly false □Definitely false
My health is excellent
□Definitely true □Mostly true □Don't know □Mostly false □Definitely false
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APPENDIX 7: Morisky Medication Adherence Scales‐8
Participant ID: ________________ Date: __________________
1) Do you sometimes forget to take your pills?
2) People sometimes miss taking their medications for reasons other than forgetting.
Thinking over the past two weeks, were there any days when you did not take your
medicine?
3) Have you ever cut back or stopped taking your medicine without telling your doctor
because you felt worse when you took it?
4) When you travel or leave home, do you sometimes forget to bring along your medicine?
5) Did you take all your medicine yesterday?
6) When you feel like your symptoms are under control, do you sometimes stop taking your
medicine?
7) Taking medicine every day is a real inconvenience for some people. Do you ever feel
hassled about sticking to your treatment plan?
8) How often do you have difficulty remembering to take all your medicine?
___A. Never/rarely
___B. Once in a while
___C. Sometimes
___D. Usually
___E. All the time
Adherence MMAS-8 Score
High Adherence 0
Medium Adherence 1-2
Low Adherence 3-8
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APPENDIX 8: Data Collection Matrix
To be completed by Pharmacist Participants for each Patient Participant at their site.
Measure
Visit 1
Baseline
assessment
Visit 2
2-week
Follow-up
Visit 3
3-month
Follow-up
Patient demographics √
Chronic Pain & Treatment History √
Current pain medications √
Other Medical Conditions √
Current Other Medications √
Substance Use History √
SF-36 √
√
BPI √ √ √
MMAS-8 √ √ √
Care Plan Recommendations √ √ √
Recommendations acceptance rates –
patients, prescribers
√ √
Pain treatment changes √ √
Other data collection from pharmacist participants:
Pharmacist & pharmacy characteristics (start of study).
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Data Collection Item Detail
Pharmacist data for each patient (sections completed at times indicated in matrix)
Participant ID: Date: / /
Patient Demographics
Age: Sex (specify):
Marital status:
1. Married/Stable relationship2. Single3. Widowed4. Divorced
Highest level of education completed:
1. None 2. Elementary school 3. High School
4. Technical/college/university 5. Graduate/professional education
Employment status:
1. Employed 2. Unemployed 3. Retired 4. Other (specify)
After tax Income
1. <$20,000 2. $20,000-$80,000 3. >$80,000
Medication coverage (all that apply)
1. Private/employment drug plan 2. ODB 3. Self-pay
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Chronic Pain and Treatment History
Types of chronic pain:
1. Nociceptive 2. Neuropathic 3. Mixed 4. Unclear 5. Other
How long has patient suffered chronic pain (in years)?
Specify Diagnosis: 1. 2. Unclear/unknown
Past medications for chronic pain:
Name or type of each
Reason for stopping (REPEAT x 5 medications)
1. Ineffective 2. Too expensive 3. Side-effects 4. Other
Non-pharmacologic treatments in current use:
1. Physiotherapy 2. Exercise 3. Acupuncture 4. Surgery 5. Relaxation therapy
6. Chiropractor 7. Other
Indicate the effectiveness of each non-pharmacological treatment in current use:
1. Effective 2. Minimally effective 3. Ineffective 4. Harmful 5. Other
Current Medications for Pain
List name, daily dose, schedule (regular/prn):
Other Medical Conditions
List:
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Other Medications in Current Use
List:
History of Substance Use
For each substance listed below:
1. Ever used (tried even once): yes/no
2. Current use: yes/no
3. Use ever a problem for patient: yes/no
4. Current problem for patient: yes/no
5. Pharmacist comments: yes/no
Nicotine, alcohol, cannabis, heroin, other non-prescribed opioids, cocaine, hallucinogens,
inhalants, non- prescribed amphetamines, non-prescribed methylphenidate, non-prescribed
sedatives, other (specify)
Brief Pain Inventory (BPI)
Standard measure
Short Form-36 (SF-36)
Standard measure
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8-ItemMorisky Medication Adherence Scale (MMAS-8)
Standard measure
Care Plan Recommendations
Provide free text description for each recommendation
Categorize each recommendation:
1. Medication-related 2. Referral 3. Education 4. Other
For each medication-related recommendation indicate:
1. Dose increase
2. Dose decrease
3. Schedule change
4. Reduced quantities
5. Observed dosing
6. Drug change
7. Drug discontinuation
8. Other
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Recommendations Acceptance
For each recommendation indicate:
Patient acceptance/rejection Physician acceptance/rejection
Still under consideration Modified recommendation – describe
Pain Treatment Changes
For each pain-related medication change since the last visit, indicate all that apply and specify:
Medication involved: Time since change made:
1. Dose increase 2. Dose decrease 3. Schedule change 4. Reduced quantities
5. Observed dosing 6. Drug discontinuation 7. Other
For each new pain-related medication, complete the following:
Newmedication: Time since started (days):
Total daily dose: Schedule:
type (regular/prn):
Newmedication: Time since started (days):
Total daily dose: Schedule:
type (regular/prn):
Newmedication: Time since started (days):
Total daily dose: Schedule:
type (regular/prn):
Newmedication: Time since started (days):
Total daily dose: Schedule:
type (regular/prn):
Newmedication: Time since started (days):
Total daily dose: Schedule:
type (regular/prn):
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For the changes of each non-pharmacological treatment, indicate all that apply:
Type of treatment: Time since started (days):
1. Started – effective 2. Started - effectiveness unclear
3. Changed regimen – effective 4. Changed regimen - effectiveness unclear
5. Stopped – ineffective 6. Stopped – too expensive
7. Stopped – side effects 8. Other
Type of treatment: Time since started (days):
1. Started – effective 2. Started - effectiveness unclear
3. Changed regimen – effective 4. Changed regimen - effectiveness unclear
5. Stopped – ineffective 6. Stopped – too expensive
7. Stopped – side effects 8. Other
Type of treatment: Time since started (days):
1. Started – effective 2. Started - effectiveness unclear
3. Changed regimen – effective 4. Changed regimen - effectiveness unclear
5. Stopped – ineffective 6. Stopped – too expensive
7. Stopped – side effects 8. Other
Type of treatment: Time since started (days):
1. Started – effective 2. Started - effectiveness unclear
3. Changed regimen – effective 4. Changed regimen - effectiveness unclear
5. Stopped – ineffective 6. Stopped – too expensive
7. Stopped – side effects 8. Other
Type of treatment: Time since started (days):
1. Started – effective 2. Started - effectiveness unclear
3. Changed regimen – effective 4. Changed regimen - effectiveness unclear
5. Stopped – ineffective 6. Stopped – too expensive
7. Stopped – side effects 8. Other
